Prof Timothy Price
School of Medicine
College of Health
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Tim Price MBBS FRACP DHlthSc (Med)Professor Tim Price trained in Medical oncology at the RAH and completed a Gastrointestinal Fellowship at The Royal Marsden Hospital and Institute of Cancer Research, London. He is currently Head of Clinical Oncology Research at The Queen Elizabeth Hospital, Woodville. He is also the Clinical Director of the BRAGG Comprehensive Cancer Centre of SA/NT. He has also positions as Visiting Medical Oncologist at Calvary Hospital North Adelaide, Western Hospital Henley Beach and Lyell McEwin Health Service. He is a Clinical Professor within the Faculty of Medicine, at the University of Adelaide."I am a fulltime Clinician / Translational Researcher and have been an active contributor in the field of Clinical, Epidemiological and Translational Science at National and International levels. My research focus has primarily related to Clinical Trial activity, but has subsequently evolved to assessing both the impact of Clinical Trial data and its translation into standard practice as reflected by changes in practice and evidence for improved outcomes, together with more basic translational research by improving the understanding of the molecular pathways currently relevant in colorectal cancer (in particular the vascular endothelial growth factor pathway and the epithelial growth factor path way)". My main Clinical Research focus is in the area of Gastrointestinal Cancers, Neuroendocrine Tumours and Phase 1 trials.
My research focus over the last five years has been primarily investigating the relevance of the EGFR and VEGF pathways in advanced colorectal cancer. Via a collaboration with investigators of the MAX trail, a large International Randomised Phase 3 study of anti-VEGF therapy and chemotherapy, and the Basil Hetzel Institute my team investigated the proposed cross talk between the EGFR and VEGF pathways and the potential of KRAS/RAS, BRAF, PTEN and PIC3CA as predictors of anti-VEGF therapy. Furthermore our laboratory also assessed novel predictors of resistance to anti-EGFR therapy. As part of the AGITG collaboration I was a member of the Clinical Trial Management Team that produced and presented the evidence to support KRAS mutation as a predictor of non-response to anit-EGFR therapy and the subsequent NEJM paper. This data has led to changes in clinical practice internationally. It is now well recognised that KRAS and RAS mutation testing should be an integral part of standard clinical practice in advanced colorectal care and this is now mandated prior to prescribing anti-EGFR therapy. These findings have led to significant improvements in patient care preventing access to these agents in patients who will be resistant to them and therefore reducing the impact on quality of life of an ineffective therapy. This also has obviously implications for the Health Care System in terms of cost savings. Ongoing investigation of alternate pathways and markers continue to be a focus of our laboratory and this will lead to further honour’s projects.
Basic/Translational Science
Beyond the ongoing work around the EGFR pathway, the recent focus of our laboratory has been also to look at novel therapies and currently we are investigating the role of aquaporin in the development of metastatic disease in advanced colorectal cancer. As part of this research focus I will supervise a PhD student (Dr Yoko Tomita) to further assess the potential for this novel targeted agent in preventing metastatic potential using a number of preclinical models with a view to early phase Clinical Trials in man to follow. The link with my Clinical Research unit at TQEH and experience in Phase I trials will allow this to progress in a timely fashion.
Clinical Research/Science
As is supported by the recent publications on anti-EGFR therapy my clinical trial program has led to significant roles in this area of practice. As a member of the international steering committee for the Panitumumab 181 study, we have confirmed the activity of a combination regimen of chemotherapy and panitumumab (anti-EGFR agent) in second line colorectal cancer. Furthermore we have also provided additional literature on extended RAS mutation status, the first such evidence in the second line setting, which has reinforced the international trend away from purely KRAS exon 2 mutation testing to an all RAS mutation testing platform for advanced colorectal cancer. As the co-chair of the International Randomised Study (ASPECTT trial) comparing the two available anti-EGFR agents (Cetuximab and Panitumumab), our work has led to the first evidence of non-inferiority of both agents and therefore because of differing toxicity and delivery scheduling, this has allowed clinicians and funders to assess the optimal agent to be used in their own clinical settings based on logistics rather than efficacy.
Translational and Epidemiological/Population Health Colorectal Research.
As part of my membership of the Adelaide Colorectal Tumour Group and the Scientific Advisory committee that oversees the South Australian metastatic colorectal registry, there have been a number of areas of population research undertaken (see CV). Firstly there has been the epidemiological or population health based analysis relating to changes in clinical practice and outcomes for metastatic colorectal cancer resulting from the new agents available, and the evolution of surgical care and radiological technology over time. Our group has led reviews of the impact of late recurrence, primary site of colorectal cancer and outcome for advanced disease, improved survival with new systemic therapies in standard care and care and outcome patterns in the geriatric colorectal cancer space, to name a few. The breadth of this research can be evidenced by my attached publication list, which highlights a number of areas of research that I have both led and designed or collaborated in. Over site of the Registry for metastatic colorectal cancer and the subsequent projects is an important component of my role as a member of the Scientific Advisory Committee of the registry.
In keeping with my international profile I have been a member of the ESMO Colorectal Guidelines Group, initially publishing in 2012. The guidelines are currently being reviewed and are due to be published in an updated form later in 2016. Furthermore, as part of the Adelaide Colorectal Tumour Group and together with international collaborators we have published three Australian consensus documents on clinical care for advanced colorectal cancer which I have lead, together with a gastric cancer consensus document. This ongoing collaboration will lead to a further consensus meeting and updated guidelines in Vienna this year. In addition because of my National profile I have been recently asked to chair the NHMRC/Cancer Council Colorectal Guidelines and this will be a two year project overseeing the review of data and updating of guidelines for all aspects of colorectal cancer including prevention, screening and management of localised and advanced colorectal cancer.
| Date | Position | Institution name |
|---|---|---|
| 2016 - ongoing | Professor | University of Adelaide |
| 2008 - 2015 | Associate Professor | University of Adelaide |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2012 - 2014 | University of Adelaide | Australia | Doctor of Health Science (Medicine) |
| 1982 - 1988 | University of Adelaide | Australia | MBBS |
| Date | Title | Institution | Country |
|---|---|---|---|
| 1999 - 2000 | Research Fellow | Institute of Cancer Research | United Kingdom |
| 1998 - 2000 | Clinical Research Fellow | The Royal Marsden NHS Foundation Trust | United Kingdom |
| RACP | University of Sydney | Australia |
| Year | Citation |
|---|---|
| 2025 | Piercey, O., Chantrill, L., Hsu, H. C., Ma, B., Price, T., Tan, I. B., . . . Desai, J. (2025). Expert consensus on the optimal management of BRAFV600E-mutant metastatic colorectal cancer in the Asia-Pacific region. Asia Pacific Journal of Clinical Oncology, 21(1), 31-45. Scopus1 Europe PMC2 |
| 2025 | Depauw, L., Townsend, A., Karapetis, C., Roy, A., Wigg, A., Tebbutt, N. C., . . . Price, T. (2025). Role of locoregional therapy including liver transplantation in liver-only metastatic colorectal cancer: a review paper. Expert Review of Anticancer Therapy, 25(1), 41-53. Scopus1 |
| 2025 | Bellas, O. M., Cao, K., Bowen, J., Smid, S., Shakib, S., Crawford, G. B., . . . Wardill, H. R. (2025). Medicinal CANnabis (CBD/THC) to prevent the symptoms and side effects of chemotherapy in people with advanced CANcer (CANCAN): protocol for a phase II, randomised, double-blind, placebo-controlled trial. BMJ Open, 15(3), e089336-1-e089336-10. Scopus1 Europe PMC1 |
| 2025 | Altus, L. M., Forster, J. C., Mercurio, J., Kitchener, M., Corsini, N., Nenke, M., . . . Cehic, G. (2025). South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival. ESMO Gastrointestinal Oncology, 8(C), 1-10. |
| 2025 | Bedrikovetski, S., Murshed, I., Fitzsimmons, T., Traeger, L., Price, T. J., Penniment, M., . . . Sammour, T. (2025). Total neoadjuvant therapy in early-onset rectal cancer: A multicentre prospective cohort study.. Colorectal Dis, 27(3), e70059. Scopus1 WoS2 Europe PMC2 |
| 2025 | Price, T., Depauw, L., Cehic, G., Wachter, E., Sebben, R., Reid, J., . . . Maddern, G. (2025). A phase 1 study to assess the safety, tolerability and effectiveness of PV-10 (Rose Bengal Sodium) in neuroendocrine tumours metastatic to the liver.. Br J Cancer, 132(10), 888-896. Scopus3 WoS3 Europe PMC2 |
| 2025 | Yip, D., Zalcberg, J., Blay, J. Y., Eriksson, M., Espinoza, D., Price, T., . . . Joensuu, H. (2025). Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial: Clinical Studies. British Journal of Cancer, 132(10), 897-904. Scopus2 WoS2 Europe PMC2 |
| 2025 | Foley, K., Reid, J., Edwards, S., Price, T., Zimet, A., Woods, S., . . . Hewett, P. (2025). Pressurised intraperitoneal aerosol chemotherapy (PIPAC): The first Australian experience. Pleura and Peritoneum, 10(1), 25-31. |
| 2025 | Price, T., Lugowska, I., Chawla, S. P., Falchook, G., Subbiah, V., Monzon, J. G., . . . Prenen, H. (2025). A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours. BMJ Open, 15(5), 11 pages. |
| 2025 | Xu, C., Cheng, X., Liu, C., Ren, J., Shelat, V. G., Price, T., . . . Wang, Y. (2025). Efficacy observation of sequential TAS-102 following regorafenib as a later-line treatment in patients with metastatic colorectal cancer: a cohort study. Journal of Gastrointestinal Oncology, 16(2), 354-366. |
| 2025 | Chan, M., Krishnan, T., Townsend, A., Karapetis, C., Roy, A., Foo, T., . . . Price, T. (2025). The current landscape of neoadjuvant therapy for resectable colon cancer. Expert Review of Anticancer Therapy, 25(8), 901-913. Scopus1 |
| 2025 | Kaur, H., Litinas, M. -C., Lauder, C., Da Silva, N., Bradshaw, E. L., Price, T., . . . Hewett, P. (2025). Long-Term Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Pseudomyxoma Peritonei: A 22-Year Single Institution Experience. ANZ Journal of Surgery, 95(10), 2112-2122. |
| 2025 | Hofheinz, R. D., Fokas, E., Benhaim, L., Price, T. J., Arnold, D., Beets-Tan, R., . . . Martinelli, E. (2025). Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology, 36(9), 1007-1024. Scopus30 Europe PMC22 |
| 2025 | Lew, J. B., Worthington, J., Ge, H., Luo, Q., Feletto, E., Canfell, K., & Price, T. (2025). Re-evaluating population-level screening recommendations to address increasing early-onset colorectal cancer rates in Australia: a modelling study. ESMO Gastrointestinal Oncology, 7, 100136. Scopus3 |
| 2025 | Jin, C. W., Lv, S. Y., Yang, C., Tan, M., Shelat, V. G., Ambe, P. C., . . . Liu, H. (2025). Most eligible candidates for primary tumor resection among metastatic colorectal cancer patients: a SEER-based population analysis. Translational Cancer Research, 14(7), 4381-4398. Scopus1 |
| 2025 | Rad, S. K., Li, R., Yeo, K. K. L., Cooksley, C., Shaghayegh, G., Vreugde, S., . . . Smith, E. (2025). Cell Line-Dependent Internalization, Persistence, and Immunomodulatory Effects of Staphylococcus aureus in Triple-Negative Breast Cancer. Cancers, 17(18), 2947-1-2947-25. Scopus2 WoS2 Europe PMC1 |
| 2025 | Sobrero, A., Dasari, A., Aquino, J., Lonardi, S., Garcia-Carbonero, R., Elez, E., . . . Eng, C. (2025). Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study. European Journal of Cancer, 218, 9 pages. Scopus4 WoS3 Europe PMC2 |
| 2025 | Rad, S. K., Yeo, K. K. L., Wu, F., Li, R., Nourmohammadi, S., Tomita, Y., . . . Smith, E. (2025). A Systematic Review and Meta-Analysis of 16S rRNA and Cancer Microbiome Atlas Datasets to Characterize Microbiota Signatures in Normal Breast, Mastitis, and Breast Cancer. Microorganisms, 13(2), 467-1-467-24. Scopus6 WoS5 Europe PMC5 |
| 2025 | Burge, M. E., Espinoza, D., Sjoquist, K. M., Siu, D. H., Mercieca-Bebber, R., Chantrill, L. A., . . . Tebbutt, N. C. (2025). AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG). Clinical Colorectal Cancer, 24(2), 120-128. |
| 2025 | Rad, S. K., Yeo, K. K. L., Li, R., Wu, F., Liu, S., Nourmohammadi, S., . . . Smith, E. (2025). Enhancement of Doxorubicin Efficacy by Bacopaside II in Triple-Negative Breast Cancer Cells. Biomolecules, 15(1), 55-1-55-17. Scopus6 WoS6 Europe PMC4 |
| 2025 | Kianpour Rad, S., Li, R., Yeo, K. K. L., Wu, F., Tomita, Y., Price, T. J., . . . Smith, E. (2025). Bacterial Infections and Their Cell Wall Ligands Differentially Modulate Doxorubicin Sensitivity in Triple-Negative Breast Cancer Cells. Microorganisms, 13(10), 17 pages. |
| 2025 | Moore, E. K., Gordon, C., Gauvin, B., Price, T. J., Slee, M., Wardill, H. R., . . . Bowen, J. M. (2025). Protocol for the TMaC Study: A patient-blinded, randomised, sham-controlled, parallel-group study evaluating effects of repetitive Transcranial Magnetic stimulation on chronic Chemotherapy-induced pain in bowel cancer patients. Biomedicine Hub, 10(1), 1-19. |
| 2024 | White, C., Wardill, H., Paul, C., Price, T., Karapetis, C., Nalder, M., . . . Scott, R. J. (2024). DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol. BMC cancer, 24(1), 1369. Scopus2 WoS2 Europe PMC2 |
| 2024 | Foo, T., Roy, A., Karapetis, C., Townsend, A., & Price, T. (2024). Metastatic colorectal cancer- third line therapy and beyond. Expert Review of Anticancer Therapy, 24(5), 219-227. Scopus1 WoS1 Europe PMC1 |
| 2024 | Kimber, J. S., Symonds, E., Uylaki, W., Horsnell, M., Drew, P. A., Smith, E., . . . Price, T. J. (2024). Exploring the associations between colorectal polyps and type 2 diabetes mellitus in a colonoscopy clinic population. ESMO Gastrointestinal Oncology, 4, 7 pages. Scopus1 |
| 2024 | Li, R., Liu, S., Yeo, K., Edwards, S., Li, M. Y., Santos, R., . . . Smith, E. (2024). Diagnostic and prognostic significance of circulating secreted frizzled-related protein 5 in colorectal cancer. Cancer Medicine, 13(11), e7352-1-e7352-11. Europe PMC1 |
| 2024 | Kawazoe, A., Xu, R. H., García-Alfonso, P., Passhak, M., Teng, H. W., Shergill, A., . . . Kochenderfer, M. (2024). Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Journal of Clinical Oncology, 42(24), 2918-2927. Scopus45 Europe PMC46 |
| 2024 | Chen, C., Luo, X., Tang, W., Geng, H., Martínez-Pérez, J., Price, T., . . . Zhang, Y. (2024). Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study. Journal of Gastrointestinal Oncology, 15(4), 1497-1507. Scopus2 WoS1 Europe PMC1 |
| 2024 | Man Ying Li, C., Li, R., Drew, P., Price, T., Smith, E., Maddern, G. J., . . . Fenix, K. (2024). Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: current strategies and future challenges. Cancer Treatment Reviews, 122, 102665-1-102665-11. Scopus15 WoS12 Europe PMC10 |
| 2024 | Vasconcelos, J. P. S., Chen, N., Titmuss, E., Tu, D., Brule, S. Y., Goodwin, R., . . . Loree, J. M. (2024). Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials. Clinical Cancer Research, 30(6), 1121-1130. Scopus6 WoS5 Europe PMC5 |
| 2024 | Li, C. M. Y., Tomita, Y., Dhakal, B., Tin, T., Li, R., Wright, J. A., . . . Fenix, K. (2024). Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases. Cancer Immunology Immunotherapy, 73(1), 6-1-6-16. Scopus2 WoS1 Europe PMC2 |
| 2023 | Bedrikovetski, S., Traeger, L., Fitzsimmons, T., Price, T. J., Ruszkiewicz, A. R., Vather, R., & Sammour, T. (2023). Association between RAS/BRAF mutations and complete response following total neoadjuvant therapy in patients with rectal cancer: a prospective multicentered study. Annals of Surgical Oncology, 31(3), 1681-1689. Scopus8 WoS7 Europe PMC6 |
| 2023 | Wyrwicz, L., Taieb, J., Price, T., Bachet, J. -B., Karthaus, M., Vidot, L., . . . Heinemann, V. (2023). Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies. COLORECTAL CANCER, 12(3), 11 pages. WoS1 |
| 2023 | Roy, A., Shepherdson, M., Gormly, K., Byrne, S., Pedersen, S., Price, T., . . . Symonds, E. L. (2023). Circulating tumour DNA and MRI circumferential resection margin are key prognostic indicators for survival in rectal cancer. ESMO Gastrointestinal Oncology, 2, 100013-1-100013-7. |
| 2023 | Kumarasinghe, M. P., Houghton, D., Allanson, B. M., & Price, T. J. (2023). What Therapeutic Biomarkers in Gastro-Esophageal Junction and Gastric Cancer Should a Pathologist Know About?. Surgical Pathology Clinics, 16(4), 659-672. Scopus1 Europe PMC1 |
| 2023 | Mikaeel, R. R., Edwards, S., Winter, J. M., Young, J. P., Young, G. P., Price, T., & Symonds, E. L. (2023). Age-Specific Differences in the Risk of Colorectal Precursor Lesions Among Patients with Type 2 Diabetes Undergoing Surveillance Colonoscopy.. Asian Pacific journal of cancer prevention : APJCP, 24(5), 1769-1779. Scopus1 |
| 2023 | M. Naeini, M., Newell, F., Aoude, L. G., Bonazzi, V. F., Patel, K., Lampe, G., . . . Waddell, N. (2023). Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy. Nature Communications, 14(1), 17 pages. Scopus19 WoS17 Europe PMC17 |
| 2023 | Shepherdson, M., Kilburn, D., Ullah, S., Price, T., Karapetis, C. S., Nguyen, P., . . . Roy, A. C. (2023). Survival outcomes for patients with colorectal cancer with synchronous liver only metastasis. ANZ Journal of Surgery, 93(7-8), 1847-1853. Scopus5 WoS4 Europe PMC4 |
| 2023 | Dhakal, B., Tomita, Y., Drew, P., Price, T., Maddern, G., Smith, E., & Fenix, K. (2023). Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects. Molecules, 28(8), 3624. Scopus16 WoS15 Europe PMC14 |
| 2023 | Li, C. M. Y., Tomita, Y., Dhakal, B., Li, R., Li, J., Drew, P., . . . Fenix, K. A. (2023). Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis. Journal for ImmunoTherapy of Cancer, 11(4), e006764-1-e006764-17. Scopus19 WoS18 Europe PMC16 |
| 2023 | Krishnan, T., Wang, F., Karapetis, C., Roy, A., & Price, T. (2023). Primary site and treatment impact in unresectable metastatic colorectal cancer. Expert Review of Anticancer Therapy, 23(6), 617-623. Scopus1 WoS1 Europe PMC1 |
| 2023 | Jiang, D. M., Parshad, S., Zhan, L., Sim, H. W., Siu, L. L., Liu, G., . . . Chen, E. X. (2023). Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. Clinical Colorectal Cancer, 22(4), 457-463. Scopus2 WoS2 Europe PMC2 |
| 2023 | Guccione, L., Gough, K., Drosdowsky, A., Price, T., Pavlakis, N., Wyld, D., . . . Schofield, P. (2023). The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis.. Support Care Cancer, 31(10), 1-11. Scopus2 WoS2 Europe PMC1 |
| 2023 | Geerinckx, B., Teuwen, L. A., Foo, T., Vandamme, T., Smith, A., Peeters, M., & Price, T. (2023). Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 23(12), 1237-1249. Scopus5 WoS5 Europe PMC5 |
| 2023 | Wardill, H. R., Wooley, L. T., Bellas, O. M., Cao, K., Cross, C. B., van Dyk, M., . . . Price, T. J. (2023). Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges. British Journal of Cancer, 130(1), 19-30. Scopus4 WoS3 Europe PMC4 |
| 2023 | Taieb, J., Price, T., Vidot, L., Chevallier, B., Wyrwicz, L., & Bachet, J. B. (2023). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy. BMC Cancer, 23(1), 11 pages. Scopus12 WoS11 Europe PMC10 |
| 2023 | Li, M., Chan, D. L., Tapia Rico, G., Cehic, G., Lawrence, B., Wyld, D., . . . Pavlakis, N. (2023). Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy. Neuroendocrinology, 113(3), 281-288. Scopus6 WoS4 Europe PMC3 |
| 2023 | Bedrikovetski, S., Traeger, L., Price, T. J., Carruthers, S., Selva-Nayagam, S., Moore, J. W., & Sammour, T. (2023). Can sarcopenia predict complete response after total neoadjuvant therapy in advanced rectal cancer? A multicentre observational cohort study. Journal of Surgical Oncology, 128(1), 75-84. Scopus18 WoS16 Europe PMC13 |
| 2023 | Lam, L. L., Pavlakis, N., Shitara, K., Sjoquist, K. M., Martin, A. J., Yip, S., . . . Goldstein, D. (2023). INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer, 23(1), 12 pages. Scopus13 WoS14 Europe PMC21 |
| 2022 | Nguyen, M., Segelov, E., Goldstein, D., Pavlakis, N., Shapiro, J., Price, T. J., . . . Roy, A. C. (2022). Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 22(1), 39-51. |
| 2022 | Mikaeel, R. R., Young, J. P., Li, Y., Smith, E., Horsnell, M., Uylaki, W., . . . Price, T. J. (2022). Survey of germline variants in cancer-associated genes in young adults with colorectal cancer. Genes Chromosomes and Cancer, 61(2), 105-113. Scopus9 WoS8 Europe PMC7 |
| 2022 | Alawawdeh, A., Price, T., Karapetis, C., Piantadosi, C., Padbury, R., Roy, A., . . . Townsend, A. R. (2022). Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry.. Asia Pac J Clin Oncol, 18(4), 428-433. Scopus1 WoS1 |
| 2022 | Shepherdson, M., Leemaqz, S., Singh, G., Ryder, C., Ullah, S., Canuto, K., . . . Barreto, S. G. (2022). Young-Onset Gastrointestinal Adenocarcinoma Incidence and Survival Trends in the Northern Territory, Australia, with Emphasis on Indigenous Peoples. Cancers, 14(12), 14 pages. Scopus10 WoS10 Europe PMC8 |
| 2022 | Dean, A., Gill, S., McGregor, M., Broadbridge, V., Järveläinen, H. A., & Price, T. (2022). Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. Lancet Gastroenterology and Hepatology, 7(10), 943-951. Scopus58 WoS56 Europe PMC48 |
| 2022 | Pavlakis, N., Tincknell, G., Lim, L. E., Muro, K., Obermannova, R., Lorenzen, S., . . . Lordick, F. (2022). European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. Therapeutic Advances in Medical Oncology, 14, 17 pages. Scopus5 WoS5 |
| 2022 | Krishnan, T., Roberts-Thomson, R., Broadbridge, V., & Price, T. (2022). Targeting Mutated KRAS Genes to Treat Solid Tumours. Molecular Diagnosis and Therapy, 26(1), 39-49. Scopus18 WoS15 Europe PMC10 |
| 2022 | Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., . . . Price, T. J. (2022). Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncology, 23(1), 115-124. Scopus262 WoS247 Europe PMC227 |
| 2022 | Chionh, F., Gebski, V., Al-Obaidi, S. J., Mooi, J. K., Bruhn, M. A., Lee, C. K., . . . Tebbutt, N. C. (2022). VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. Scientific Reports, 12(1), 14 pages. Scopus15 WoS13 Europe PMC9 |
| 2022 | Smith, A., Roy, A., Karapetis, C. S., Broadbridge, V., & Price, T. (2022). Immunotherapy use in oesophagogastric cancers—a review of the literature. British Journal of Cancer, 127(1), 21-29. Scopus3 WoS3 Europe PMC3 |
| 2022 | Foo, T., Goldstein, D., Segelov, E., Shapiro, J., Pavlakis, N., Desai, J., . . . Roy, A. C. (2022). The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. Targeted Oncology, 17(2), 95-110. Scopus5 WoS5 Europe PMC3 |
| 2022 | Smith, A., Geerinckx, B., & Price, T. J. (2022). Insights from the IDEA Collaboration: Are They Enough?. Journal of Clinical Oncology, 40(16), 1843-1844. Scopus1 WoS1 Europe PMC1 |
| 2022 | Mikaeel, R. R., Young, J. P., Li, Y., Poplawski, N. K., Smith, E., Feng, J., . . . Price, T. J. (2022). RNF43 pathogenic Germline variant in a family with colorectal cancer. Clinical Genetics, 101(1), 122-126. Scopus8 WoS8 Europe PMC7 |
| 2022 | Liu, Z., Martin, J. H., Liauw, W., McLachlan, S. A., Link, E., Matera, A., . . . Michael, M. (2022). Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites. European Journal of Clinical Pharmacology, 78(1), 53-64. Scopus1 WoS1 Europe PMC1 |
| 2022 | Guccione, L., Gough, K., Drosdowsky, A., Price, T., Pavlakis, N., Wyld, D., . . . Schofield, P. (2022). The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. Patient Education and Counseling, 105(1), 212-220. Scopus5 WoS4 Europe PMC4 |
| 2022 | Chan, D. L., Pavlakis, N., Crumbaker, M., Lawrence, B., Barber, C., Price, T. J., . . . Oberg, K. (2022). Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series. Asia Pacific Journal of Clinical Oncology, 18(3), 209-216. Scopus2 WoS2 |
| 2021 | Michael, M., Chantrill, L., Price, T., Chan, D. L., Wakelin, K., & Cummins, M. (2021). Real-world management and patient perspectives on QOL with neuroendocrine tumors: An ANZ perspective. Asia Pacific Journal of Clinical Oncology, 17(S2), 3-10. Scopus1 WoS1 Europe PMC1 |
| 2021 | Tomita, Y., Smith, E., Palethorpe, H. M., Nakhjavani, M., Yeo, K. K. L., Townsend, A. R., . . . Hardingham, J. E. (2021). In vitro synergistic inhibition of HT-29 proliferation and 2H-11 and HUVEC tubulogenesis by bacopaside I and II Is associated with Ca²⁺ flux and loss of plasma membrane integrity. Pharmaceuticals, 14(5), 1-18. Scopus5 WoS4 Europe PMC2 |
| 2021 | Nakhjavani, M., Smith, E., Yeo, K., Palethorpe, H. M., Tomita, Y., Price, T. J., . . . Hardingham, J. E. (2021). Anti-angiogenic properties of ginsenoside rg3 epimers: in vitro assessment of single and combination treatments. Cancers, 13(9, article no. 2223), 1-20. Scopus22 WoS20 Europe PMC17 |
| 2021 | Mikaeel, R. R., Young, J. P., Tapia Rico, G., Hewett, P. J., Hardingham, J. E., Uylaki, W., . . . Price, T. J. (2021). Immunohistochemistry features and molecular pathology of appendiceal neoplasms. Critical Reviews in Clinical Laboratory Sciences, 58(6), 369-384. Scopus15 WoS12 Europe PMC11 |
| 2021 | Loree, J. M., Dowers, A., Tu, D., Jonker, D. J., Edelstein, D. L., Quinn, H., . . . Kopetz, S. (2021). Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial. Clinical Cancer Research, 27(1), 52-59. Scopus22 WoS21 Europe PMC19 |
| 2021 | Mooi, J., Chionh, F., Savas, P., Da Gama Duarte, J., Chong, G., Brown, S., . . . Tebbutt, N. C. (2021). Dual antiangiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study. Clinical Cancer Research, 27(8), 2159-2167. Scopus16 WoS1 Europe PMC11 |
| 2021 | Li, M., Roder, D., D'Onise, K., Walters, D., Farshid, G., Buckley, E., . . . Olver, I. (2021). Female breast cancer treatment and survival in South Australia: Results from linked health data.. Eur J Cancer Care (Engl), 30(5), 1-12. Scopus3 WoS3 Europe PMC3 |
| 2021 | Michael, M., Liauw, W., McLachlan, S. A., Link, E., Matera, A., Thompson, M., . . . Burge, M. E. (2021). Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study. Cancer Chemotherapy and Pharmacology, 88(1), 39-52. Scopus4 WoS2 Europe PMC3 |
| 2021 | Schmoll, H. J., Stein, A., van Cutsem, E., Price, T., Hofheinz, R. D., Nordlinger, B., . . . Haustermans, K. (2021). Pre- And postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. Journal of Clinical Oncology, 39(1), 17-29. Scopus86 WoS74 Europe PMC63 |
| 2021 | Mikaeel, R. R., Symonds, E. L., Kimber, J., Smith, E., Horsnell, M., Uylaki, W., . . . Young, J. P. (2021). Young-onset colorectal cancer is associated with a personal history of type 2 diabetes. Asia Pacific Journal of Clinical Oncology, 17(1), 131-138. Scopus25 WoS23 Europe PMC19 |
| 2021 | Alawawdeh, A., Krishnan, T., Roy, A., Karapetis, C., Joshi, R., Singhal, N., & Price, T. (2021). Curative therapy for rectal cancer. Expert Review of Anticancer Therapy, 21(2), 193-203. Scopus8 WoS7 Europe PMC6 |
| 2021 | Mikaeel, R., Young, J. P., Tapia Rico, G., Hardingham, J. E., Hewett, P. J., Symonds, E. L., . . . Price, T. J. (2021). Appendiceal Neoplasm Incidence and Mortality Rates are on the Rise in Australia. Expert Review of Gastroenterology and Hepatology, 15(2), 203-210. Scopus6 WoS7 Europe PMC5 |
| 2021 | Bernhardt, S. M., Dasari, P., Glynn, D. J., Woolford, L., Moldenhauer, L. M., Walsh, D., . . . Ingman, W. V. (2021). Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours.. BMC Cancer, 21(1), 736-1-736-12. Scopus4 WoS5 Europe PMC3 |
| 2021 | Sartore-Bianchi, A., García-Alfonso, P., Geissler, M., Köhne, C. H., Peeters, M., Price, T., . . . Modest, D. P. (2021). Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 20(4), 305-313. Scopus4 WoS3 Europe PMC2 |
| 2021 | Nakhjavani, M., Smith, E., Palethorpe, H. M., Tomita, Y., Yeo, K., Price, T. J., . . . Hardingham, J. E. (2021). Anti-Cancer Effects of an Optimised Combination of Ginsenoside Rg3 Epimers on Triple Negative Breast Cancer Models. Pharmaceuticals, 14(7), 12-20. Scopus12 WoS11 Europe PMC8 |
| 2021 | Dunn, C., Hong, W., Gibbs, P., Ackland, S., Sjoquist, K., Tebbutt, N. C., . . . Burge, M. (2021). Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group: First-Line Therapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 20(3), 245-255. Scopus3 WoS3 Europe PMC2 |
| 2021 | Bernhardt, S. M., Dasari, P., Glynn, D. J., Townsend, A. R., Price, T. J., & Ingman, W. V. (2021). Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells.. Breast Cancer Research and Treatment, 187(3), 681-693. Scopus3 WoS3 Europe PMC2 |
| 2021 | Nakhjavani, M., Smith, E., Yeo, K., Tomita, Y., Price, T. J., Yool, A., . . . Hardingham, J. E. (2021). Differential antiangiogenic and anticancer activities of the active metabolites of ginsenoside Rg3. Journal of Ginseng Research, 48(2), 10 pages. Scopus8 WoS9 Europe PMC7 |
| 2021 | Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., . . . Govindan, R. (2021). Sotorasib for lung cancers with KRAS P.G12C mutation. New England Journal of Medicine, 384(25), 2371-2381. Scopus1365 WoS1297 Europe PMC1169 |
| 2021 | Siu, H. W. D., Tebbutt, N., Chantrill, L., Karapetis, C., Steer, C., Wilson, K., . . . Burge, M. (2021). MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC Cancer, 21(1), 9 pages. Scopus4 WoS2 Europe PMC2 |
| 2021 | Reid, J. L., Kanhere, H. A., Hewett, P. J., Price, T. J., Maddern, G. J., & Trochsler, M. I. (2021). Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol. Pleura and Peritoneum, 6(4), 151-154. Scopus5 WoS3 Europe PMC3 |
| 2021 | Vanlint, A. S., Adams, J., & Price, T. (2021). COVID-19 prompts rapid and safe transition of chemotherapy into homes. Australian Health Review, 45(6), 782-783. Scopus2 WoS1 Europe PMC2 |
| 2021 | Abbas, M. N., Bright, T., Price, T., Karapetis, C., Thompson, S., Connell, C., . . . Roy, A. (2021). Patterns of care and outcomes for gastric and gastro-oesophageal junction cancer in an Australian population. ANZ Journal of Surgery, 91(12), 2675-2682. Scopus4 WoS4 Europe PMC3 |
| 2021 | Alawawdeh, A., Piantadosi, C., Townsend, A. R., Karapetis, C. S., Padbury, R., Roy, A. C., . . . Price, T. J. (2021). Prognostic differences of RAS mutations: Results from South Australian (SA) Metastatic Colorectal Registry.. Targeted Oncology, 17(1), 35-41. Scopus4 WoS5 Europe PMC5 |
| 2021 | Sassi, C., Capozzo, R., Hammer, M., Zecca, C., Federoff, M., Blauwendraat, C., . . . Logroscino, G. (2021). Exploring dementia and neuronal ceroid lipofuscinosis genes in 100 FTD-like patients from 6 towns and rural villages on the Adriatic Sea cost of Apulia. SCIENTIFIC REPORTS, 11(1), 11 pages. WoS8 |
| 2021 | McNeill, D., Karapetis, C., Price, T., Meagher, P., Piantadosi, C., Quinn, S., . . . Roy, A. (2021). Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: results from the South Australian Metastatic Colorectal Cancer Registry. Internal Medicine Journal, 51(1), 69-77. Scopus2 WoS2 Europe PMC2 |
| 2020 | Fontana, E., Nyamundanda, G., Cunningham, D., Tu, D., Cheang, M. C. U., Jonker, D. J., . . . Sadanandam, A. (2020). Intratumoral transcriptome heterogeneity is associated with patient prognosis and sidedness in patients with colorectal cancer treated with Anti-EGFR therapy from the CO.20 trial. JCO Precision Oncology, 4(4), 1152-1162. Scopus5 WoS6 Europe PMC6 |
| 2020 | Tie, J., Cohen, J. D., Lo, S. N., Wang, Y., Li, L., Christie, M., . . . Gibbs, P. (2020). Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 148(4), 1014-1026. Scopus92 WoS90 Europe PMC81 |
| 2020 | Price, T., Ang, A., Boedigheimer, M., Kim, T. W., Li, J., Cascinu, S., . . . Peeters, M. (2020). Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biology and Therapy, 21(10), 891-898. Scopus19 WoS18 Europe PMC24 |
| 2020 | Chong, L. C., Hardingham, J. E., Townsend, A. R., Piantadosi, C., Rico, G. T., Karapetis, C., . . . Price, T. J. (2020). Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry.. Target Oncol, 15(6), 751-757. Scopus12 WoS11 Europe PMC11 |
| 2020 | Price, T. J., Piantadosi, C., Townsend, A. R., Padbury, R., Roy, A. C., Moore, J., . . . Karapetis, C. S. (2020). Prognostic differences of RAS mutations: Results from South Australian (SA) metastatic colorectal (mCRC) registry.. JOURNAL OF CLINICAL ONCOLOGY, 38(15), 2 pages. WoS3 |
| 2020 | Nakhjavani, M., Smith, E., Townsend, A. R., Price, T. J., & Hardingham, J. E. (2020). Anti-Angiogenic Properties of Ginsenoside Rg3. Molecules Basel Switzerland, 25(21), 18 pages. Scopus78 WoS72 Europe PMC57 |
| 2020 | Bernhardt, S. M., Dasari, P., Walsh, D., Townsend, A. R., Price, T. J., & Ingman, W. V. (2020). Timing of breast cancer surgery during the menstrual cycle-is there an optimal time of the month?. Oncology Letters, 20(3), 2045-2057. Scopus8 WoS3 Europe PMC4 |
| 2020 | Prasanna, T., Wong, R., Price, T., Shapiro, J., Tie, J., Wong, H. L., . . . Yip, D. (2020). Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. Current Problems in Cancer, 45(1), 1-9. Scopus17 WoS17 Europe PMC16 |
| 2020 | Bernhardt, S. M., Dasari, P., Wrin, J., Raymond, W., Edwards, S., Walsh, D., . . . Ingman, W. V. (2020). Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age. Breast Cancer Research, 22(1), 90-1-90-10. Scopus16 WoS15 Europe PMC14 |
| 2020 | Bernhardt, S. M., Dasari, P., Walsh, D., Raymond, W., Hull, M. L., Townsend, A. R., . . . Ingman, W. V. (2020). The menstrual cycle is an under-appreciated factor in premenopausal breast cancer diagnosis and treatment. Current Opinion in Endocrine and Metabolic Research, 15, 37-42. Scopus5 |
| 2020 | Tomita, Y., Moldovan, M., Chang Lee, R., Hsieh, A. H., Townsend, A., & Price, T. (2020). Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. The Cochrane database of systematic reviews, 2020(11), 121 pages. Scopus3 Europe PMC14 |
| 2020 | Rico, G. T., Townsend, A., Price, T., & Patterson, K. (2020). Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response. BMJ Case Reports, 13(12), 6 pages. Scopus7 WoS9 Europe PMC8 |
| 2020 | Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., . . . Li, B. T. (2020). KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. The New England journal of medicine, 383(13), 1207-1217. Scopus1399 WoS1306 Europe PMC1199 |
| 2020 | Clarke, S. J., Burge, M., Feeney, K., Gibbs, P., Jones, K., Marx, G., . . . Tebbutt, N. C. (2020). The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. PLoS ONE, 15(3), e0229900. Scopus16 WoS13 Europe PMC11 |
| 2020 | Lau, D. K., Burge, M., Roy, A., Chau, I., Haller, D. G., Shapiro, J. D., . . . Price, T. J. (2020). Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 20(4), 251-270. Scopus5 WoS4 Europe PMC3 |
| 2020 | Roy, A. C., Shapiro, J., Burge, M., Karapetis, C. S., Pavlakis, N., Segelov, E., . . . Price, T. (2020). Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 20(4), 305-324. WoS1 |
| 2020 | Narasimhan, V., Wright, J. A., Churchill, M., Wang, T., Rosati, R., Lannagan, T. R., . . . Woods, S. L. (2020). Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy. Clinical Cancer Research, 26(14), 1-26. Scopus155 WoS136 Europe PMC135 |
| 2020 | Price, T., Burge, M., Chantrill, L., Gibbs, P., Pavlakis, N., Shapiro, J., & Sjoquist, K. (2020). Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. Asia Pacific Journal of Clinical Oncology, 16(S1), 3-12. Scopus3 WoS2 Europe PMC2 |
| 2020 | Bachet, J. B., Wyrwicz, L., Price, T., Cremolini, C., Phelip, J. M., Portales, F., . . . Falcone, A. (2020). Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open, 5(3), 1-10. Scopus39 WoS40 Europe PMC28 |
| 2020 | Taniguchi, H., Yamanaka, T., Sakai, D., Muro, K., Yamazaki, K., Nakata, S., . . . Price, T. (2020). Efficacy of panitumumab and cetuximab in patients with colorectal cancer previously treated with bevacizumab; a combined analysis of individual patient data from aspecct and wjog6510g. Cancers, 12(7), 1-11. Scopus11 WoS10 Europe PMC8 |
| 2020 | Li, M., Roder, D., D'Onise, K., Walters, D., Farshid, G., Buckley, E., . . . Olver, I. (2020). Monitoring TNM stage of female breast cancer and survival across the South Australian population, with national and international TNM benchmarking: A population-based cohort study. BMJ Open, 10(6), e037069. Scopus7 WoS7 Europe PMC4 |
| 2019 | Holden, C. A., Poprawski, D., Singhal, N., Buckley, E., Caruso, J., Wichmann, M. W., & Price, T. (2019). A systematic scoping review of determinants of multidisciplinary cancer team access and decision-making in the management of older patients diagnosed with colorectal cancer. Journal of Geriatric Oncology, 11(6), 909-916. Scopus8 WoS8 Europe PMC6 |
| 2019 | Nguyen, T. H., Stansborough, J., Ong, G. J., Surikow, S., Price, T. J., & Horowitz, J. D. (2019). Antecedent cancer in Takotsubo syndrome predicts both cardiovascular and long-term mortality.. Cardio-Oncology, 5(1), 20-1-20-9. Scopus13 WoS11 Europe PMC5 |
| 2019 | Taieb, J., Geissler, M., Rivera, F., Karthaus, M., Wilson, R., Loupakis, F., . . . Peeters, M. (2019). Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clinical Colorectal Cancer, 18(4), 245-256.e5. Scopus6 WoS5 Europe PMC4 |
| 2019 | Palethorpe, H. M., Smith, E., Tomita, Y., Nakhjavani, M., Yool, A. J., Price, T. J., . . . Hardingham, J. E. (2019). Bacopasides I and II act in synergy to inhibit the growth, migration and invasion of breast cancer cell lines. Molecules, 24(19), 3539-1-3539-16. Scopus37 WoS32 Europe PMC25 |
| 2019 | Roder, D., Karapetis, C. S., Olver, I., Keefe, D., Padbury, R., Moore, J., . . . Price, T. (2019). Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival.. BMJ open, 9(9), 1-11. Scopus30 WoS22 Europe PMC24 |
| 2019 | Li, M., Olver, I., Keefe, D., Holden, C., Worthley, D., Price, T., . . . Roder, D. (2019). Pre-diagnostic colonoscopies reduce cancer mortality - Results from linked population-based data in South Australia. BMC Cancer, 19(1), 856. Scopus10 WoS8 Europe PMC3 |
| 2019 | Nakhjavani, M., Hardingham, J., Palethorpe, H., Price, T. J., & Townsend, A. R. (2019). Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer. Journal of Breast Cancer, 22(3), 341-361. Scopus45 WoS45 Europe PMC37 |
| 2019 | Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., . . . Lipford, J. R. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 575(7781), 217-223. Scopus1737 WoS1289 Europe PMC1577 |
| 2019 | Woodhouse, B., Pattison, S., Segelov, E., Singh, S., Parker, K., Kong, G., . . . Lawrence, B. (2019). Consensus-derived quality performance indicators for neuroendocrine tumour care. Journal of Clinical Medicine, 8(9), 12 pages. Scopus7 WoS6 Europe PMC3 |
| 2019 | McGregor, M., & Price, T. J. (2019). IMblaze 370: lessons learned and future strategies in colorectal cancer treatment. ANNALS OF TRANSLATIONAL MEDICINE, 7(21), 5 pages. WoS6 Europe PMC3 |
| 2019 | Guccione, L., Gough, K., Drosdowsky, A., Fisher, K., Price, T., Pavlakis, N., . . . Schofield, P. (2019). Defining the supportive care needs and psychological morbidity of patients with functioning versus nonfunctioning neuroendocrine tumors: Protocol for a phase 1 trial of a nurse-led online and phone-based intervention. Jmir Research Protocols, 8(12), 12 pages. Scopus4 WoS4 Europe PMC4 |
| 2019 | Jameson, M. B., Gormly, K., Espinoza, D., Hague, W., Asghari, G., Jeffery, G. M., . . . Ackland, S. P. (2019). SPAR - A randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: An AGITG clinical trial. BMC Cancer, 19(1), 12 pages. Scopus15 WoS15 Europe PMC13 |
| 2019 | Burzykowski, T., Coart, E., Saad, E. D., Shi, Q., Sommeijer, D. W., Bokemeyer, C., . . . Wolmark, N. (2019). Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2(9), E1911750. Scopus12 WoS11 Europe PMC11 |
| 2019 | Nakhjavani, M., Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. J., Yool, A. J., . . . Hardingham, J. E. (2019). Stereoselective anti-cancer activities of ginsenoside Rg3 on triple negative breast cancer cell models. Pharmaceuticals, 12(3), 117-1-117-14. Scopus43 WoS36 Europe PMC30 |
| 2019 | Price, T., Shen, L., Ma, B., Esser, R., Chen, W., Gibbs, P., . . . Cheng, A. L. (2019). Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer. Asia Pacific Journal of Clinical Oncology, 15(4), 225-230. Scopus5 WoS5 Europe PMC3 |
| 2019 | Burge, M., Price, T., & Karapetis, C. S. (2019). First-line therapy for metastatic colorectal cancer: Current perspectives and future directions. Asia Pacific Journal of Clinical Oncology, 15(S1), 3-14. Scopus12 WoS10 Europe PMC7 |
| 2019 | Young, J., Price, T. J., Hardingham, J., Symonds, E., Smith, E., Ruszkiewicz, A., . . . Poplawski, N. (2019). Type 2 diabetes as a potential risk marker for early onset colorectal cancer.. JOURNAL OF CLINICAL ONCOLOGY, 37(15), 2 pages. WoS1 |
| 2019 | Tang, M., Joensuu, H., Simes, R. J., Price, T. J., Yip, S., Hague, W., . . . Zalcberg, J. (2019). Challenges of international oncology trial collaboration-a call to action. British Journal of Cancer, 121(7), 515-521. Scopus29 WoS27 Europe PMC24 |
| 2019 | Nakhjavani, M., Hardingham, J. E., Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. J., & Townsend, A. R. (2019). Ginsenoside Rg3: Potential molecular targets and therapeutic indication in metastatic breast cancer. Medicines, 6(1), 17-1-17-20. Europe PMC41 |
| 2019 | Chong, L. C., Townsend, A. R., Young, J., Roy, A., Piantadosi, C., Hardingham, J. E., . . . Price, T. J. (2019). Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry. Targeted Oncology, 14(1), 85-91. Scopus12 WoS12 Europe PMC11 |
| 2019 | Smith, E., Tomita, Y., Palethorpe, H. M., Howell, S., Nakhjavani, M., Townsend, A. R., . . . Hardingham, J. E. (2019). Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation. Epigenetics, 14(2), 158-170. Scopus11 WoS9 Europe PMC10 |
| 2019 | Tapia Rico, G., Price, T., Tebbutt, N., Hardingham, J., Lee, C., Buizen, L., . . . Townsend, A. (2019). Right or left primary site of colorectal cancer: outcomes from the molecular analysis of the AGITG MAX Trial. Clinical Colorectal Cancer, 18(2), 141-148. Scopus21 WoS20 Europe PMC16 |
| 2019 | Peeters, M., Price, T., Boedigheimer, M., Kim, T. W., Ruff, P., Gibbs, P., . . . Ang, A. (2019). Evaluation of emergent mutations in circulating cell-free DNA and clinical outcomes in patients with metastatic colorectal cancer treated with panitumumab in the ASPECCT study. Clinical Cancer Research, 25(4), 1216-1225. Scopus41 WoS37 Europe PMC31 |
| 2019 | Chong, L. C., Karapetis, C., Roy, A., Padbury, R., & Price, T. J. (2019). Authors’ Reply to Yu: “Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry”. Targeted Oncology, 14(3), 367-368. |
| 2019 | Tomita, Y., Palethorpe, H. M., Smith, E., Nakhjavani, M., Townsend, A. R., Price, T. J., . . . Hardingham, J. E. (2019). Bumetanide-derived aquaporin 1 inhibitors, AqB013 and AqB050 inhibit tube formation of endothelial cells through induction of apoptosis and impaired migration in vitro. International Journal of Molecular Sciences, 20(8), 1818-1-1818-11. Scopus20 WoS22 Europe PMC20 |
| 2019 | McGregor, M., & Price, T. J. (2019). Moving miRNAs to therapeutic targets in colorectal cancer. Ebiomedicine, 43, 13-14. |
| 2019 | Wells, J. C., Tu, D., Siu, L. L., Shapiro, J. D., Jonker, D. J., Karapetis, C., . . . O'Callaghan, C. J. (2019). Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. Clinical Colorectal Cancer, 18(1), e140-e149. Scopus6 WoS4 Europe PMC4 |
| 2019 | Tie, J., Cohen, J. D., Wang, Y., Li, L., Christie, M., Simons, K., . . . Gibbs, P. (2019). Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: A prospective biomarker study. Gut, 68(4), 663-671. Scopus295 WoS279 Europe PMC258 |
| 2018 | Palethorpe, H., Tomita, Y., Smith, E., Pei, J., Townsend, A., Price, T., . . . Hardingham, J. (2018). The aquaporin 1 inhibitor bacopaside II reduces endothelial cell migration and tubulogenesis and induces apoptosis. International Journal of Molecular Sciences, 19(3), 653-1-653-10. Scopus31 WoS31 Europe PMC23 |
| 2018 | Tang, M., Price, T. J., Shapiro, J., Gibbs, P., Haller, D. G., Arnold, D., . . . Burge, M. (2018). Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Review of Anticancer Therapy, 18(4), 339-349. Scopus6 WoS7 Europe PMC5 |
| 2018 | Tapia Rico, G., & Price, T. J. (2018). Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. Expert Opinion on Biological Therapy, 18(4), 449-457. Scopus32 WoS28 Europe PMC26 |
| 2018 | Price, T. (2018). Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer. The Lancet Oncology, 19(5), 587-589. Scopus4 WoS4 Europe PMC1 |
| 2018 | Lau, D. K., Tay, A. Y., yeung, Y., Chionh, F., Mooi, J., Murone, C., . . . Tebbutt, N. C. (2018). Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol study. British Journal of Cancer, 118(7), 966-971. Scopus48 WoS40 Europe PMC39 |
| 2018 | Townsend, A., Tebbutt, N., Karapetis, C., Cooper, P., Singhal, N., Yeend, S., . . . Price, T. (2018). Phase IB/II study of second-line therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS wild-type metastatic colorectal cancer. Clinical Cancer Research, 24(16), 3838-3844. Scopus8 WoS6 Europe PMC5 |
| 2018 | McGregor, M., & Price, T. J. (2018). Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. Future Oncology, 14(24), 2437-2459. Scopus8 WoS8 Europe PMC8 |
| 2018 | Tapia Rico, G., Karapetis, C., Townsend, A. R., Piantadosi, C., Padbury, R., Roy, A., . . . Price, T. J. (2018). Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry. Acta Oncologica, 57(11), 1455-1457. Scopus3 WoS3 Europe PMC3 |
| 2018 | Wong, G. Y. M., Kumar, R., Beeke, C., Ullah, S., Chen, J., Karapetis, C. S., . . . Padbury, R. (2018). Response to: "consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients with Colorectal Liver Metastases". Annals of Surgery, 268(1), e9-e10. |
| 2018 | Adelson, P., Fusco, K., Karapetis, C., Wattchow, D., Joshi, R., Price, T., . . . Roder, D. (2018). Use of guideline-recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia. Journal of Evaluation in Clinical Practice, 24(1), 135-144. Scopus16 WoS14 Europe PMC15 |
| 2018 | Goey, K. K. H., Sørbye, H., Glimelius, B., Adams, R. A., André, T., Arnold, D., . . . Koopman, M. (2018). Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 100, 35-45. Scopus31 WoS30 Europe PMC29 |
| 2018 | Jonker, D. J., Nott, L., Yoshino, T., Gill, S., Shapiro, J., Ohtsu, A., . . . O'Callaghan, C. J. (2018). Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. The Lancet Gastroenterology and Hepatology, 3(4), 263-270. Scopus152 WoS146 Europe PMC131 |
| 2018 | Sultana, A., Meng, R., Piantadosi, C., Brooke-Smith, M., Chen, J., Dolan, P., . . . Padbury, R. (2018). Liver resection for colorectal cancer metastases: a comparison of outcomes over time in South Australia. HPB, 20(4), 340-346. Scopus10 WoS11 Europe PMC9 |
| 2018 | Lee, R., Kanhere, H., Trochsler, M., Broadbridge, V., Maddern, G., & Price, T. (2018). Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?. World Journal of Gastrointestinal Oncology, 10(8), 211-220. Scopus9 WoS9 Europe PMC5 |
| 2018 | Shapiro, J. D., Thavaneswaran, S., Underhill, C. R., Robledo, K. P., Karapetis, C. S., Day, F. L., . . . Segelov, E. (2018). Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer, 17(4), 313-319. Scopus13 WoS11 Europe PMC10 |
| 2018 | Tapia Rico, G., Li, M., Pavlakis, N., Cehic, G., & Price, T. J. (2018). Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. Cancer Treatment Reviews, 66, 1-6. Scopus38 WoS30 Europe PMC27 |
| 2018 | Mooi, J. K., Wirapati, P., Asher, R., Lee, C. K., Savas, P., Price, T. J., . . . Tebbutt, N. C. (2018). The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Annals of Oncology, 29(11), 2240-2246. Scopus114 WoS109 Europe PMC104 |
| 2018 | Shepshelovich, D., Townsend, A. R., Espin-Garcia, O., Latifovic, L., O Callaghan, C. J., Jonker, D. J., . . . Liu, G. (2018). Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Medicine, 7(11), 5478-5487. Scopus20 WoS21 Europe PMC20 |
| 2018 | Kim, T. W., Peeters, M., Thomas, A., Gibbs, P., Hool, K., Zhang, J., . . . Price, T. (2018). Impact of emergent circulating tumor DNA Ras mutation in panitumumab-treated chemoresistant metastatic colorectal cancer. Clinical Cancer Research, 24(22), 5602-5609. Scopus52 WoS47 Europe PMC41 |
| 2018 | Klevansky, M., Vatandoust, S., Dykes, L., Padbury, R., Price, T. J., Roder, D., . . . Karapetis, C. (2018). The impact of primary tumour resection and sidedness in patients with synchronous metastatic colorectal cancer (mCRC): findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC). Journal of Clinical Oncology, 36(4, article no. 739), 1. |
| 2018 | Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., . . . Shapiro, J. (2018). Targeted therapy for metastatic colorectal cancer. Expert Review of Anticancer Therapy, 18(10), 991-1006. Scopus46 WoS43 Europe PMC36 |
| 2018 | Prasanna, T., Karapetis, C. S., Roder, D., Tie, J., Padbury, R., Price, T., . . . Yip, D. (2018). The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncologica, 57(11), 1438-1444. Scopus88 WoS83 Europe PMC78 |
| 2018 | Smith, E., Palethorpe, H. M., Tomita, Y., Pei, J., Townsend, A. R., Price, T. J., . . . Hardingham, J. E. (2018). The purified extract from the medicinal plant Bacopa monnieri, bacopaside II, inhibits growth of colon cancer cells in vitro by inducing cell cycle arrest and apoptosis. Cells, 7(7), 81-1-81-11. Scopus56 WoS51 Europe PMC40 |
| 2018 | Peeters, M., Price, T., Taieb, J., Geissler, M., Rivera, F., Canon, J. L., . . . Siena, S. (2018). Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. British Journal of Cancer, 119(3), 303-312. Scopus36 WoS36 Europe PMC26 |
| 2018 | Sud, S., O’callaghan, C., Jonker, C., Karapetis, C., Price, T., Tebbutt, N., . . . Goodwin, R. (2018). Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response. Current Oncology, 25(6), e516-e526. Scopus13 Europe PMC13 |
| 2018 | Gibbs, P., Heinemann, V., Sharma, N. K., Taieb, J., Ricke, J., Peeters, M., . . . Gordon, M. (2018). Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clinical Colorectal Cancer, 17(4), e617-e629. Scopus63 WoS54 Europe PMC42 |
| 2018 | Leyden, J., Pavlakis, N., Chan, D., Michael, M., Clarke, S., Khasraw, M., & Price, T. (2018). Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. Asia Pacific Journal of Clinical Oncology, 14(3), 256-263. Scopus10 WoS10 Europe PMC6 |
| 2018 | Taieb, J., Falcone, A., Lonardi, S., Price, T. J., Bachet, J. B., Wyrwicz, L., . . . Van Cutsem, E. (2018). Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii155. Scopus1 WoS1 |
| 2018 | Falcone, A., André, T., Edeline, J., François, E., Taieb, J., Phelip, J., . . . Seitz, J. (2018). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v104-v105. Scopus2 WoS13 |
| 2018 | Schmoll, H., Haustermans, K., Price, T., Nordlinger, B., Hofheinz, R., Daisne, J., . . . Van Cutsem, E. (2018). PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v107. Scopus1 WoS1 |
| 2018 | Price, T. (2018). Convenor's Welcome. Asia-Pacific Journal of Clinical Oncology, 14(S3), 6. |
| 2018 | Wong, G., Kumar, R., Beeke, C., Ullah, S., Chen, J., Karapetis, C., . . . Padbury, R. (2018). Survival Outcomes for Patients with Indeterminate 18 FDG-PET Scan for Extrahepatic Disease before Liver Resection for Metastatic Colorectal Cancer: A Retrospective Cohort Study Using a Prospectively Maintained Database to Analyze Survival Outcomes for Patients with Indeterminate Extrahepatic Disease on 18FDG-PET Scan before Liver Resection for Metastatic Colorectal Cancer. Annals of Surgery, 267(5), 929-935. Scopus8 WoS8 Europe PMC2 |
| 2017 | Tapia Rico, G., Townsend, A. R., Broadbridge, V., & Price, T. J. (2017). Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs and Aging, 34(3), 173-189. Scopus5 WoS4 Europe PMC4 |
| 2017 | Parry, S., Burt, R. W., Win, A. K., Aung, Y. K., Woodall, S., Arnold, J., . . . Young, J. P. (2017). Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance. The New Zealand Medical Journal, 130(1451), 57-67. Scopus16 WoS13 Europe PMC4 |
| 2017 | Chan, D. L., Sjoquist, K. M., Goldstein, D., Price, T. J., Martin, A. J., Bang, Y. J., . . . Pavlakis, N. (2017). The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. PLoS ONE, 12(2), 16 pages. Scopus14 WoS13 Europe PMC12 |
| 2017 | Chong, L., Healey, T., Michele, T., & Price, T. (2017). Capecitabine in locally advanced anal cancer, do we need randomised evidence?. Expert Review of Anticancer Therapy, 17(5), 411-416. Scopus5 WoS4 Europe PMC2 |
| 2017 | Price, T. J. (2017). Advanced colorectal cancer treatment options beyond standard systemic therapy. Lancet Oncology, 18(2), 157-159. Scopus11 WoS12 Europe PMC10 |
| 2017 | Kumar, S., Tomita, Y., Wrin, J., Bruhn, M., Swalling, A., Mohammed, M., . . . Hardingham, J. (2017). High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. Clinical and Translational Oncology, 19(6), 718-726. Scopus12 WoS15 Europe PMC11 |
| 2017 | Tomita, Y., Dorward, H., Yool, A. J., Smith, E., Townsend, A. R., Price, T. J., & Hardingham, J. E. (2017). Role of aquaporin 1 signalling in cancer development and progression. International Journal of Molecular Sciences, 18(2), 299-1-299-17. Scopus94 WoS89 Europe PMC75 |
| 2017 | Marshall-Webb, M., Bright, T., Price, T., Thompson, S., & Watson, D. (2017). Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy. Diseases of the Esophagus, 30(2), 1-7. Scopus26 WoS24 Europe PMC17 |
| 2017 | Canavese, M., Ngo, D., Maddern, G., Hardingham, J., Price, T., & Hauben, E. (2017). Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. International Journal of Cancer, 140(10), 2183-2191. Scopus39 WoS34 Europe PMC28 |
| 2017 | Linke, K., Tapia Rico, G., & Price, T. J. (2017). Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients. Medical Care, 55(1), 86. |
| 2017 | Finlay, B., Price, T., & Hewett, P. (2017). Neutropenia and thrombocytopenia after cytoreductive surgery and heated intraperitoneal chemotherapy. Pleura and Peritoneum, 2(3), 137-141. Scopus5 WoS5 Europe PMC4 |
| 2017 | Peeters, M., Price, T., Taieb, J., Geissler, M., Rivera, F., Canon, J. L., . . . Siena, S. (2017). Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment. Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii113-iii114. Scopus1 |
| 2017 | Falcone, A., Seitz, J. F., Price, T., Wyrwicz, L., Dorbon, A., Lopez Busto, N., . . . Van Cutsem, E. (2017). The international open-label early-access study of trifluridine/tipiracil (TAS-102) in patients with pretreated metastatic colorectal cancer (phase IIIb). Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii124. |
| 2017 | Price, T. J., Karapetis, C. S., Piantadosi, C., Padbury, R., Roy, A. C., Maddern, G., . . . Townsend, A. R. (2017). Nonagenarian patients with metastatic colorectal cancer: results from the South Australian metastatic colorectal cancer registry. Journal of Clinical Oncology, 25(4), 1. |
| 2017 | Roy, A. C., Karapetis, C. S., Piantadosi, C., Townsend, A. R., Padbury, R., Carruthers, S., . . . Price, T. J. (2017). Patterns of care for synchronous rectal cancer with liver-only metastasis: Results from the South Australian registry of metastatic colorectal cancer. Journal of Clinical Oncology, 35(4), 1. WoS1 |
| 2017 | Wong, S., Lidums, I., Rosty, C., Ruszkiewicz, A., Parry, S., Win, A., . . . Young, J. (2017). Findings in young adults at colonoscopy from a hospital service database audit. BMC Gastroenterology, 17(1), 56-1-56-9. Scopus16 WoS17 Europe PMC14 |
| 2017 | Moore, J., Price, T., Carruthers, S., Selva-Nayagam, S., Luck, A., Thomas, M., & Hewett, P. (2017). Prospective randomized trial of neoadjuvant chemotherapy during the ‘wait period’ following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial. Colorectal Disease, 19(11), 973-979. Scopus50 WoS47 Europe PMC40 |
| 2017 | Thavaneswaran, S., Kok, P. S., & Price, T. (2017). Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. Expert Review of Anticancer Therapy, 17(10), 965-979. Scopus7 WoS6 Europe PMC3 |
| 2017 | Segelov, E., Lordick, F., Goldstein, D., Chantrill, L. A., Croagh, D., Lawrence, B., . . . Price, T. J. (2017). Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 17(10), 951-964. Scopus2 WoS2 Europe PMC3 |
| 2017 | Tapia Rico, G., Klevansky, M., Townsend, A., & Price, T. (2017). Synovial metastasis of the knee in a KRAS mutant rectal adenocarcinoma patient. BMJ Case Reports, 2017, bcr-2017-220008. Scopus4 Europe PMC4 |
| 2017 | Chionh, F., Lau, D., Yeung, Y., Price, T., & Tebbutt, N. (2017). Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database of Systematic Reviews, 2017(7), CD008398. Scopus54 WoS45 Europe PMC29 |
| 2017 | Chan, D. L. H., Segelov, E., Wong, R. S. H., Smith, A., Herbertson, R. A., Li, B. T., . . . Pavlakis, N. (2017). Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews, 2017(6), 174 pages. Scopus17 WoS88 Europe PMC66 |
| 2017 | Cheng, A. L., Cornelio, G., Shen, L., Price, T., Yang, T. S., Chung, I. J., . . . Lim, R. (2017). Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer, 16(2), e73-e88. Scopus25 WoS21 Europe PMC19 |
| 2017 | Rico, G., Price, T., Karapetis, C., Piantadosi, C., Padbury, R., Roy, A., . . . Townsend, A. (2017). Brain metastasis in advanced colorectal cancer: results from the South Australian metastatic colorectal cancer (SAmCRC) registry. Cancer Biology and Medicine, 14(4), 371-376. Scopus20 WoS17 Europe PMC15 |
| 2017 | Young, J. P., Price, T. J., & Parry, S. (2017). Serrated polyposis: The problem of definition and its relationship to the population at risk for syndrome-related colorectal cancer. Translational Cancer Research, 6(Suppl 9), S1480-S1483. Scopus1 WoS1 Europe PMC1 |
| 2017 | Chandrasegaram, M. D., Gill, A. J., Samra, J., Price, T., Chen, J., Fawcett, J., & Merrett, N. D. (2017). Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer. World Journal of Gastrointestinal Oncology, 9(10), 407-415. Scopus43 WoS40 Europe PMC31 |
| 2017 | Chew, T., Bright, T., Price, T. J., Watson, D. I., & Devitt, P. G. (2017). Follow-Up Practices of Surgeons and Medical Oncologists in Australia and New Zealand Following Resection of Esophagogastric Cancers. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 23(5), 217-222. Scopus8 WoS8 Europe PMC5 |
| 2017 | Roder, D., Farshid, G., Kollias, J., Koczwara, B., Karapetis, C., Adams, J., . . . Price, T. (2017). Female breast cancer management and survival: the experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly. Journal of Evaluation in Clinical Practice, 23(6), 1433-1443. Scopus6 WoS7 Europe PMC5 |
| 2017 | Price, T. J., Hardingham, J., Karapetis, C., Smith, E., Padbury, R., Roy, A., . . . Townsend, A. (2017). Bevacizumab first line and impact on subsequent anti-EGFR activity. Annals of Oncology, 28(S5), 178. |
| 2017 | Wasan, H. S., Gibbs, P., Sharma, N. K., Taieb, J., Heinemann, V., Ricke, J., . . . Limentani, S. (2017). First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncology, 18(9), 1159-1171. Scopus323 WoS270 Europe PMC219 |
| 2016 | Harrison, S. J., Mainwaring, P., Price, T., Millward, M. J., Padrik, P., Underhill, C. R., . . . Spencer, A. (2016). Phase i clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: Study NPI-0052-102 final results. Clinical Cancer Research, 22(18), 4559-4566. Scopus71 WoS60 Europe PMC54 |
| 2016 | Tomita, Y., Hsieh, A., Yuan, Y., Townsend, A., & Price, T. (2016). Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Cochrane Database of Systematic Reviews, 2016(2). Scopus14 |
| 2016 | Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2016). Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly. European Journal of Cancer Care, 25(5), 753-763. Scopus4 WoS4 Europe PMC4 |
| 2016 | Patel, D., Townsend, A. R., Karapetis, C., Beeke, C., Padbury, R., Roy, A., . . . Price, T. J. (2016). Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry. Annals of Surgical Oncology, 23(11), 3616-3622. Scopus17 WoS17 Europe PMC13 |
| 2016 | Gormly, K. L., Coscia, C., Wells, T., Tebbutt, N., Harvey, J. A., Wilson, K., . . . Price, T. (2016). MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial. Journal of Medical Imaging and Radiation Oncology, 60(5), 607-615. Scopus7 WoS7 Europe PMC6 |
| 2016 | Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., . . . Arnold, D. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 27(8), 1386-1422. Scopus2907 WoS2715 Europe PMC2299 |
| 2016 | Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., . . . Gibbs, P. (2016). Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 8(346), 1-10. Scopus1202 WoS1125 Europe PMC984 |
| 2016 | Patel, D., Chan, D., Cehic, G., Pavlakis, N., & Price, T. (2016). Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Review of Endocrinology and Metabolism, 11(4), 311-327. Scopus3 WoS1 Europe PMC1 |
| 2016 | Price, T., Thavaneswaran, S., Burge, M., Segelov, E., Haller, D., Punt, C., . . . Shapiro, J. (2016). Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert Review of Anticancer Therapy, 16(5), 557-571. Scopus6 WoS6 Europe PMC6 |
| 2016 | Schofield, P., Stockler, M., Zannino, D., Tebbutt, N., Price, T., Simes, R., . . . Jefford, M. (2016). Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. Support Care Cancer, 24(1), 401-408. Scopus34 WoS33 Europe PMC28 |
| 2016 | Perera, T., Townsend, A., Price, T., Moldovan, M., & Roberts-Thomson, R. (2016). VENOUS THROMBOEMBOLISM: WHAT DO OUR PATIENTS KNOW?. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 12, 66-67. |
| 2016 | Segelov, E., Waring, P., Desai, J., Wilson, K., Gebski, V., Thavaneswaran, S., . . . Shapiro, J. (2016). ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 16(1), 8 pages. Scopus15 WoS15 Europe PMC14 |
| 2016 | Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Robledo, K., Gebski, V., . . . Shapiro, J. (2016). Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro-intestinal trials group ICECREAM study. Journal of Clinical Oncology, 34(19), 2258-2264. Scopus54 WoS51 Europe PMC43 |
| 2016 | Bernhardt, S. M., Dasari, P., Walsh, D., Townsend, A. R., Price, T. J., & Ingman, W. V. (2016). Hormonal modulation of breast cancer gene expression: implications for intrinsic subtyping in premenopausal women. Frontiers in Oncology, 6(NOV), 241-1-241-16. Scopus32 WoS29 Europe PMC18 |
| 2016 | Townsend, A., Chong, L., Karapetis, C., & Price, T. (2016). Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treatment Reviews, 50, 148-154. Scopus25 WoS20 Europe PMC11 |
| 2016 | Price, T., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., . . . Peeters, M. (2016). Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. European Journal of Cancer, 68, 51-59. Scopus59 WoS54 Europe PMC45 |
| 2016 | Tapia Rico, G., Townsend, A. R., Klevansky, M., & Price, T. J. (2016). Liver metastases resection for gastric and esophageal tumors: is there enough evidence to go down this path?. Expert Review of Anticancer Therapy, 16(12), 1219-1225. Scopus6 WoS5 Europe PMC3 |
| 2016 | Graham, C. N., Maglinte, G. A., Schwartzberg, L. S., Price, T. J., Knox, H. N., Hechmati, G., . . . Fakih, M. G. (2016). Economic Analysis of Panitumumab Compared with Cetuximab in Patients with Wild-type KRAS Metastatic Colorectal Cancer That Progressed after Standard Chemotherapy. Clinical Therapeutics, 38(6), 1376-1391. Scopus10 WoS10 Europe PMC8 |
| 2016 | Tebbutt, N., Price, T., Ferraro, D., Wong, N., Veillard, A., Hall, M., . . . Gebski, V. (2016). Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British Journal of Cancer, 114(5), 505-509. Scopus45 WoS42 Europe PMC35 |
| 2016 | Chandrasegaram, M., Chen, J., Price, T., Zalcberg, J., Sjoquist, K., & Merrett, N. (2016). Advances in molecular pathology and treatment of periampullary cancers. Pancreas, 45(1), 32-39. Scopus24 WoS23 Europe PMC18 |
| 2016 | Vatandoust, S., Price, T., Ullah, S., Roy, A., Beeke, C., Young, J., . . . Karapetis, C. (2016). Metastatic colorectal cancer in young adults: a study from the South Australian Population-Based Registry. Clinical Colorectal Cancer, 15(1), 32-36. Scopus45 WoS43 Europe PMC33 |
| 2016 | Wilson, E., Thompson, S., Bull, J., Jones, B., Price, T., Devitt, P., . . . Bright, T. (2016). Improving care for patients with oesophageal and gastric cancer: impact of a statewide multidisciplinary team. ANZ Journal of Surgery, 86(4), 270-273. Scopus14 WoS13 Europe PMC12 |
| 2016 | Young, J. P., Price, T. J., Moore, J., & Ruszkiewicz, A. R. (2016). Human intestinal spirochetosis and its relationship to sessile serrated adenomas in an Australian population. Pathology Research and Practice, 212(8), 751-753. Scopus3 WoS3 Europe PMC4 |
| 2016 | Dorward, H., Du, A., Bruhn, M., Wrin, J., Pei, J., Evdokiou, A., . . . Hardingham, J. (2016). Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro. Journal of Experimental & Clinical Cancer Research, 35(1), 36-1-36-9. Scopus69 WoS65 Europe PMC58 |
| 2016 | Liu, G., Tu, D., Lewis, M., Cheng, D., Sullivan, L., Chen, Z., . . . Dobrovic, A. (2016). Fc-γ receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. Clinical Cancer Research, 22(10), 2435-2444. Scopus36 WoS34 Europe PMC28 |
| 2016 | Tomita, Y., Karapetis, C. S., Ullah, S., Townsend, A. R., Roder, D., Beeke, C., . . . Price, T. J. (2016). Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta Oncologica, 55(4), 480-485. Scopus12 WoS12 Europe PMC11 |
| 2016 | Thavaneswaran, S., & Price, T. (2016). Optimal therapy for resectable rectal cancer. Expert Review of Anticancer Therapy, 16(3), 285-302. |
| 2016 | Tomita, Y., Karapetis, C., Roder, D., Beeke, C., Hocking, C., Roy, A., . . . Price, T. (2016). Comparable survival outcome of metastatic colorectal cancer in Indigenous and non-Indigenous patients: Retrospective analysis of the South Australian metastatic colorectal cancer registry. Australian Journal of Rural Health, 24(2), 85-91. Scopus3 WoS3 Europe PMC3 |
| 2016 | Price, T. J., Beeke, C., Townsend, A. R., Lo, L., Amitesh, R., Padbury, R., . . . Karapetis, C. (2016). BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?. Molecular Diagnosis and Therapy, 20(1), 75-82. Scopus8 WoS7 Europe PMC5 |
| 2015 | Vatandoust, S., Price, T. J., & Karapetis, C. S. (2015). Colorectal cancer: Metastases to a single organ. World Journal of Gastroenterology, 21(41), 11767-11776. Scopus259 WoS256 Europe PMC218 |
| 2015 | Lo, L., Patel, D., Townsend, A., & Price, T. (2015). Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology, 11(12), 1907-1924. Scopus14 WoS13 Europe PMC12 |
| 2015 | Patel, G., Ullah, S., Beeke, C., Hakendorf, P., Padbury, R., Price, T., & Karapetis, C. (2015). Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. Cancer Medicine, 4(10), 1461-1471. Scopus22 WoS23 Europe PMC24 |
| 2015 | Lo, L., Townsend, A. R., Patterson, W. K., Price, T. J., Yeend, S., Patel, D., . . . Pittman, K. B. (2015). NEOADJUVANT PACLITAXEL AND EPIRUBICIN FOR STAGE III BREAST CANCER: LONG TERM OUTCOMES OF PHASE II NAB TRIAL, ACTEC STUDY UPDATE. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 11, 57. |
| 2015 | Peeters, M., Oliner, K., Price, T., Cervantes, A., Sobrero, A., Ducreux, M., . . . Patterson, S. (2015). Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI zlone as second-line treatment for metastatic colorectal cancer. Clinical Cancer Research, 21(24), 5469-5479. Scopus170 WoS159 Europe PMC132 |
| 2015 | Schmoll, H., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., . . . Haller, D. (2015). Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant Therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. Journal of Clinical Oncology, 33(32), 3733-3740. Scopus249 WoS226 Europe PMC189 |
| 2015 | Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2015). Metastatic colorectal cancer treatment and survival: the experience of major public hospitals in South Australia over three decades. Asian Pacific Journal of Cancer Prevention, 16(14), 5923-5931. Scopus12 Europe PMC3 |
| 2015 | Chan, D., Pavlakis, N., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., & Segelov, E. (2015). Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature. PLoS One, 10(8), e0135599-1-e0135599-17. Scopus24 WoS25 Europe PMC20 |
| 2015 | Hardingham, J., Grover, P., Winter, M., Hewett, P., Price, T., & Thierry, B. (2015). Detection and clinical significance of circulating tumor cells in colorectal cancer - 20 years of progress. Molecular Medicine, 21(Suppl 1), S25-S31. Scopus129 WoS113 Europe PMC93 |
| 2015 | Price, T. J., Beeke, C., Ullah, S., Padbury, R., Maddern, G., Roder, D., . . . Karapetis, C. (2015). Does the Primary Site of Colorectal Cancer Impact Outcomes for Patients With Metastatic Disease?. Cancer, 121(6), 830-835. Scopus148 WoS134 Europe PMC109 |
| 2015 | Price, T. J., Tebbutt, N., & Townsend, A. R. (2015). Less surgery, improved survival from stage IV colorectal cancer?. JAMA Surgery, 150(8), 818. |
| 2015 | Weickhardt, A., Williams, D., Lee, C., Chionh, F., Simes, J., Murone, C., . . . Tebbutt, N. (2015). Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer, 113(1), 37-45. Scopus57 WoS51 Europe PMC43 |
| 2015 | Price, T., Bruhn, M., Lee, C., Hardingham, J., Townsend, A., Mann, K., . . . Tebbutt, N. (2015). Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer, 112(6), 963-970. Scopus36 WoS35 Europe PMC27 |
| 2015 | Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2015). Colorectal cancer treatment and survival : the experience of major public hospitals in South Australia over three decades. Asian Pacific Journal of Cancer Prevention, 16(6), 2431-2440. Scopus28 Europe PMC29 |
| 2015 | Young, J., Win, A., Rosty, C., Flight, I., Roder, D., Young, G., . . . Price, T. (2015). Rising incidence of early-onset colorectal cancer in Australia over two decades: Report and review. Journal of Gastroenterology and Hepatology, 30(1), 6-13. Scopus131 WoS129 Europe PMC109 |
| 2015 | Roohullah, A., Wong, H., Sjoquist, K., Gibbs, P., Field, K., Tran, B., . . . Chantrill, L. (2015). Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World Journal of Gastroenterology, 21(17), 5352-5358. Scopus6 WoS5 Europe PMC6 |
| 2015 | Price, T. J. (2015). Second-line therapy for metastatic colorectal cancer. Lancet Oncology, 16(5), 476-477. |
| 2015 | Chan, D. L., Pavlakis, N., Shapiro, J., Price, T. J., Karapetis, C. S., Tebbutt, N. C., & Segelov, E. (2015). Erratum: Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-Analysis of the literature (PLoS ONE (2015) 10:8 (e0135599) DOI: 10.1371/journal. pone.0135599). Plos One, 10(9), e0138916. Scopus4 |
| 2015 | Van Cutsem, E., Bang, Y. J., Feng-yi, F., Xu, J. M., Lee, K. W., Jiao, S. C., . . . Rüschoff, J. (2015). HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer, 18(3), 476-484. Scopus515 WoS480 Europe PMC426 |
| 2014 | Karapetis, C. S., Jonker, D., Daneshmand, M., Hanson, J. E., O'Callaghan, C. J., Marginean, C., . . . Lorimer, I. A. J. (2014). PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17. Clinical Cancer Research, 20(3), 744-753. Scopus153 WoS139 Europe PMC120 |
| 2014 | Gibbs, P., Gebski, V., Van Buskirk, M., Thurston, K., Cade, D. N., Van Hazel, G. A., . . . Tatsch, K. (2014). Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: The SIRFLOX study. BMC Cancer, 14(1), 10 pages. Scopus55 WoS48 Europe PMC38 |
| 2014 | Newhall, K., Price, T., Peeters, M., Kim, T. W., Li, J., Cascinu, S., . . . Sidhu, R. (2014). Frequency of S492R Mutations in the Epidermal Growth Factor Receptor: Analysis of Plasma Dna from Metastatic Colorectal Cancer Patients Treated with Panitumumab or Cetuximab Monotherapy. Annals of Oncology, 25, ii109. Scopus13 |
| 2014 | Schmoll, H. J., Haustermans, K., Price, T., Nordlinger, B., Hofheinz, R., Daisne, J. F., . . . Van Cutsem, E. (2014). Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine and Oxaliplatin Vs. Capecitabine Alone in Locally Advanced Rectal Cancer: Disease Free Survival at Interim Analysis. Annals of Oncology, 25, ii111. Scopus1 |
| 2014 | Kumar, S. S., Price, T. J., Townsend, A. R., Hocking, C., & Hardingham, J. E. (2014). Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. COLORECTAL CANCER, 3(2), 223-232. WoS1 |
| 2014 | Bruhn, M., Townsend, A., Khoon Lee, C., Shivasami, A., Price, T., Wrin, J., . . . Hardingham, J. (2014). Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International Journal of Cancer, 135(3), 731-741. Scopus32 WoS28 Europe PMC27 |
| 2014 | Sree Kumar, S., Price, T., Mohyieldin, O., Borg, M., Townsend, A., & Hardingham, J. (2014). KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model. Gastrointestinal Cancer Research, 7(1), 23-26. Scopus60 Europe PMC49 |
| 2014 | Hocking, C., Hardingham, J. E., Broadbridge, V., Wrin, J., Townsend, A. R., Tebbutt, N., . . . Price, T. J. (2014). Can we accurately report PTEN status in advanced colorectal cancer?. BMC Cancer, 14(1), 128-1-128-7. Scopus13 WoS12 Europe PMC9 |
| 2014 | Segelov, E., Chan, D., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., & Pavlakis, N. (2014). The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. British Journal of Cancer, 111(6), 1122-1131. Scopus30 WoS29 Europe PMC24 |
| 2014 | Price, T., Peeters, M., Kim, T., Li, J., Cascinu, S., Ruff, P., . . . Sidhu, R. (2014). Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. The Lancet Oncology, 15(6), 569-579. Scopus423 WoS380 Europe PMC306 |
| 2014 | Jonker, D., Karapetis, C., Harbison, C., O'Callaghan, C., Tu, D., Simes, R., . . . Khambata-Ford, S. (2014). Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer, 110(3), 648-655. Scopus72 WoS66 Europe PMC58 |
| 2014 | Carter, H., Zannino, D., John Simes, R., Schofield, D., Howard, K., Zalcberg, J., . . . Tebbutt, N. (2014). The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. European Journal of Cancer, 50(3), 535-543. Scopus13 WoS16 Europe PMC14 |
| 2014 | Sommeijer, D., Karapetis, C., Zalcberg, J., Tu, D., Jonker, D., Simes, J., . . . O'Callaghan, C. (2014). The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Acta Oncologica, 53(7), 877-884. Scopus10 WoS9 Europe PMC8 |
| 2014 | Kumar, R., Price, T., Beeke, C., Jain, K., Patel, G., Padbury, R., . . . Karapetis, C. (2014). Colorectal cancer survival: an analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. Clinical Colorectal Cancer, 13(2), 87-93. Scopus59 WoS57 Europe PMC47 |
| 2014 | Ransom, D., Wilson, K., Fournier, M., Simes, R., Gebski, V., Yip, D., . . . Price, T. (2014). Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Annals of Oncology, 25(1), 117-121. Scopus60 WoS55 Europe PMC49 |
| 2014 | Peeters, M., Price, T., Cervantes, A., Sobrero, A., Ducreux, M., Hotko, Y., . . . Sidhu, R. (2014). Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology, 25(1), 107-116. Scopus189 WoS185 Europe PMC145 |
| 2014 | Vatandoust, S., Joshi, R., Pitman, K., Esterman, A., Broadbridge, V., Adams, J., . . . Price, T. (2014). A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Supportive Care in Cancer, 22(2), 513-518. Scopus29 WoS26 Europe PMC20 |
| 2014 | Patel, G., Jain, K., Kumar, R., Strickland, A., Pellegrini, L., Slavotinek, J., . . . Karapetis, C. (2014). Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Supportive Care in Cancer, 22(1), 121-128. Scopus128 WoS111 Europe PMC98 |
| 2014 | Wan, Y., Winter, M., Delalat, B., Hardingham, J., Grover, P., Wrin, J., . . . Thierry, B. (2014). Nanostructured polystyrene well plates allow unbiased high-throughput characterization of circulating tumor cells. ACS Applied Materials and Interfaces, 6(23), 20828-20836. Scopus34 WoS33 Europe PMC22 |
| 2014 | Price, T. J., Townsend, A. R., & Peeters, M. (2014). FOLFIRI with cetuximab or bevacizumab: FIRE-3. Lancet Oncology, 15(13), e582-e583. Scopus2 WoS2 Europe PMC2 |
| 2014 | Price, T. J., Segelov, E., Burge, M., Haller, D. G., Tebbutt, N. C., Karapetis, C. S., . . . Shapiro, J. D. (2014). Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Review of Anticancer Therapy, 14(12), 1477-1493. Scopus11 WoS10 Europe PMC9 |
| 2014 | Price, T. J., Peeters, M., Ruff, P., Murugappan, S., & Sidhu, R. (2014). Authors' reply. Lancet Oncology, 15(8), e303. Scopus2 WoS2 Europe PMC2 |
| 2014 | Hocking, C., & Price, T. (2014). Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therapeutic Advances in Gastroenterology, 7(1), 20-37. Scopus28 WoS22 Europe PMC21 |
| 2014 | Bhardwaj, N., Li, M., Price, T., & Maddern, G. J. (2014). Spontaneous regression of a biopsy confirmed hepatocellular carcinoma. BMJ Case Reports, 2014, bcr2014204897-1-bcr2014204897-3. Scopus9 Europe PMC7 |
| 2014 | Hocking, C., Broadbridge, V., Karapetis, C., Beeke, C., Padbury, R., Maddern, G., . . . Price, T. (2014). Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia. Medical Journal of Australia, 201(8), 462-466. Scopus9 WoS10 Europe PMC7 |
| 2014 | Kumarasinghe, M. P., Brown, I., Raftopoulos, S., Bourke, M. J., Charlton, A., De Boer, W. B., . . . Lauwers, G. Y. (2014). Standardised reporting protocol for endoscopic resection for Barrett oesophagus associated neoplasia: Expert consensus recommendations. Pathology, 46(6), 473-480. Scopus19 WoS15 Europe PMC11 |
| 2014 | Grover, P., Cummins, A., Price, T., Roberts-Thomson, I., & Hardingham, J. (2014). Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Annals of Oncology, 25(8), 1506-1516. Scopus191 WoS173 Europe PMC154 |
| 2013 | Padman, S., Padbury, R., Beeke, C., Karapetis, C., Bishnoi, S., Townsend, A., . . . Price, T. (2013). Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy. Acta Oncologica, 52(8), 1699-1706. Scopus18 WoS15 Europe PMC17 |
| 2013 | Broadbridge, V., Karapetis, C., Beeke, C., Woodman, R., Padbury, R., Maddern, G., . . . Price, T. (2013). Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival?. British Journal of Cancer, 109(5), 1338-1343. Scopus26 WoS28 Europe PMC24 |
| 2013 | Hocking, C., Townsend, A., & Price, T. (2013). Panitumumab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 13(7), 781-793. Scopus4 WoS4 Europe PMC2 |
| 2013 | Siu, L., Shapiro, J., Jonker, D., Karapetis, C., Zalcberg, J., Simes, J., . . . O'Callaghan, C. (2013). Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC clinical trials group and AGITG co.. Journal of Clinical Oncology, 31(19), 2477-2484. Scopus112 WoS104 Europe PMC105 |
| 2013 | Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., . . . Tebbutt, N. (2013). Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Medicine, 2(3), 277-285. WoS28 Europe PMC24 |
| 2013 | Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., . . . Tabernero, J. (2013). Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Critical Reviews in Oncology Hematology, 85(2), 121-135. Scopus20 WoS18 Europe PMC15 |
| 2013 | Kumar, R., Jain, K., Beeke, C., Price, T., Townsend, A., Padbury, R., . . . Karapetis, C. (2013). A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. Cancer, 119(4), 722-728. Scopus42 WoS38 Europe PMC35 |
| 2013 | Townsend, A., Bishnoi, S., Broadbridge, V., Beeke, C., Karapetis, C., Jain, K., . . . Price, T. (2013). Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. American Journal of Clinical Oncology-Cancer Clinical Trials, 36(1), 49-52. Scopus30 WoS27 Europe PMC26 |
| 2013 | Shen, L., Shan, Y., Hu, H., Price, T., Sirohi, B., Yeh, K., . . . Chen, L. (2013). Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncology, 14(12), e535-e547. Scopus439 WoS307 Europe PMC366 |
| 2013 | Rosen, L., Lipton, L., Price, T., Belman, N., Boccia, R., Hurwitz, H., . . . Tebbutt, N. (2013). The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer, 13(242), 1-11. Scopus7 WoS9 Europe PMC9 |
| 2013 | Price, T., Segelov, E., Burge, M., Haller, D., Ackland, S., Tebbutt, N., . . . Shapiro, J. (2013). Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 13(5), 597-611. Scopus32 WoS31 Europe PMC26 |
| 2013 | Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., . . . Jonker, D. (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960. Scopus43 WoS40 Europe PMC32 |
| 2013 | Willson, K., Nott, L., Broadbridge, V., & Price, T. (2013). Hepatic encephalopathy associated with cancer or anticancer therapy. Gastrointestinal Cancer Research, 6(1), 11-16. Scopus26 Europe PMC28 |
| 2013 | Tran, G., Hack, S. P., Kerr, A., Stokes, L., Gibbs, P., Price, T., & Todd, C. (2013). Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: Implications for health-care utilization in Australia. Asia Pacific Journal of Clinical Oncology, 9(3), 239-248. Scopus8 WoS7 Europe PMC6 |
| 2013 | Leung, J. T., Kichendasse, G., Nott, L., & Price, T. (2013). Adjuvant therapy for resected pancreatic adencarcinoma (Protocol). Cochrane Database of Systematic Reviews, 2013(7). |
| 2012 | Padman, S. J., & Price, T. J. (2012). Age and treatment choices in advanced colorectal cancer. COLORECTAL CANCER, 1(4), 343-353. |
| 2012 | Karapetis, C. S., & Price, T. J. (2012). Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. COLORECTAL CANCER, 1(2), 137-148. WoS1 |
| 2012 | Price, T. (2012). ESMO consensus guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Annals of Oncology, 23(10), 2479-2516. Scopus1301 WoS1211 Europe PMC1054 |
| 2012 | Khattak, M., Martin, H., Beeke, C., Price, T., Carruthers, S., Kim, S., . . . Karapetis, C. (2012). Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clinical Colorectal Cancer, 11(4), 247-254. Scopus76 WoS71 Europe PMC67 |
| 2012 | Grover, P., Cummins, A., Price, T., Roberts-Thomson, I., & Hardingham, J. (2012). A simple, cost-effective and flexible method for processing of snap-frozen tissue to prepare large amounts of intact RNA using laser microdissection. Biochimie, 94(12), 2491-2497. Scopus10 WoS10 Europe PMC11 |
| 2012 | Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Custem, E., . . . Tebbutt, N. (2012). Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 6(2), 199-209. Scopus70 WoS63 Europe PMC55 |
| 2012 | Weickhardt, A., Price, T., Chong, G., Gebski, V., Pavlakis, N., Johns, T., . . . Tebbutt, N. (2012). Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology, 30(13), 1505-1512. Scopus91 WoS84 Europe PMC78 |
| 2012 | Vatandoust, S., Joshi, R., & Price, T. (2012). Guillain-Barré syndrome in colorectal cancer. Asia Pacific Journal of Clinical Oncology, 8(2), 205-208. Scopus4 WoS3 Europe PMC3 |
| 2012 | Broadbridge, V., Karapetis, C., & Price, T. (2012). Cetuximab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 12(5), 555-565. Scopus33 WoS26 Europe PMC25 |
| 2012 | Khattak, M., Townsend, A., Beeke, C., Karapetis, C., Luke, C., Padbury, R., . . . Price, T. (2012). Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. European Journal of Cancer, 48(9), 1293-1298. Scopus26 WoS27 Europe PMC22 |
| 2012 | Peeters, M., & Price, T. (2012). Biologic therapies in the metastatic colorectal cancer treatment continuum - applying current evidence to clinical practice. Cancer Treatment Reviews, 38(5), 397-406. Scopus71 WoS71 Europe PMC62 |
| 2012 | Millward, M., Price, T., Townsend, A., Sweeney, C., Spencer, A., Sukumaran, S., . . . Spear, M. (2012). Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs, 30(6), 2303-2317. Scopus134 WoS125 Europe PMC100 |
| 2012 | Price, T., Zannino, D., Wilson, K., Simes, R., Cassidy, J., van Hazel, G., . . . Tebbutt, N. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology, 23(6), 1531-1536. Scopus116 WoS107 Europe PMC88 |
| 2012 | Arentz, G., Chataway, T., Condina, M., Price, T., Hoffmann, P., & Hardingham, J. (2012). Increased phospho-keratin 8 isoforms in colorectal tumors associated with EGFR pathway activation and reduced apoptosis. ISRN Molecular Biology, 2012(706545), 1-8. Europe PMC3 |
| 2012 | Price, T., Townsend, A., Beeke, C., Bishnoi, S., Padbury, R., Maddern, G., & Karapetis, C. (2012). "Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again?. Asia Pacific Journal of Clinical Oncology, 8(1), 10-13. Scopus10 WoS10 Europe PMC8 |
| 2012 | Tran, G., Hack, S., Kerr, A., Stokes, L., Gibbs, P., Price, T., & Todd, C. (2012). PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE TREATMENT OF ADVANCED ESOPHAGO-GASTRIC CANCER THERAPY WITH XELODA OR 5-FLUOROURACIL (5-FU) REGIMENS: IMPLICATIONS FOR HEALTH CARE UTILISATION IN AUSTRALIA. VALUE IN HEALTH, 15(7), A426. |
| 2012 | Moualed, D., Qayyum, A., Price, T., Sharma, A., & Mahendran, S. (2012). Bilateral synchronous tonsillar carcinoma: a case series and review of the literature. European Archives of Oto-Rhino-Laryngology, 269(1), 255-259. WoS10 Europe PMC7 |
| 2012 | Ransom, D., Wilson, K., Simes, J., Yip, D., Tebbutt, N., Karapetis, C., . . . Price, T. (2012). FINAL RESULTS OF AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP (AGITG) ARCTIC STUDY - AN INTERNATIONAL AUDIT OF RALTITREXED FOR PATIENTS WITH CARDIAC TOXICITY (CT) INDUCED BY FLUOROPYRIMIDINES (FP). ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 8, 314. |
| 2011 | Bishnoi, S., & Price, T. J. (2011). Reviewing the role of cytotoxics in oesophagogastric cancer in the refractory relapsed and advanced settings. Cancer Forum, 35(3), 145-150. Scopus1 WoS1 |
| 2011 | Vickers, M. M., Karapetis, C. S., Tu, D., O'Callaghan, C. J., Price, T. J., Tebbutt, N. C., . . . Jonker, D. J. (2011). The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. WoS2 |
| 2011 | Elimova, E., O'Callaghan, C. J., Tu, D., Karapetis, C. S., Price, T. J., Zhu, L., . . . Jonker, D. J. (2011). Cetuximab (CET)-related hypersensitivity reactions (HSRs): An analysis of timing, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. WoS1 |
| 2011 | O'Callaghan, C. J., Tu, D., Karapetis, C. S., Au, H., Moore, M. J., Tebbutt, N. C., . . . Jonker, D. J. (2011). The relationship between the development of rash and clinical and quality of life outcomes by Kras mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17.. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 2 pages. |
| 2011 | O'Callaghan, C. J., Tu, D., Karapetis, C. S., Au, H., Moore, M. J., Tebbutt, N. C., . . . Jonker, D. J. (2011). The relationship between the development of rash and clinical and health-related quality of life outcomes by <i>KRAS</i> mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. WoS1 |
| 2011 | Price, T. J., Zannino, D., Wilson, K., Simes, J., Van Hazel, G. A., Robinson, B. A., . . . Tebbutt, N. C. (2011). Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. WoS2 |
| 2011 | Van Hazel, G. A., Tu, D., Tebbutt, N. C., Jonker, D. J., Price, T. J., O'Callaghan, C., . . . Karapetis, C. S. (2011). Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. WoS1 |
| 2011 | Tebbutt, N. C., Lipton, L. R., Price, T. J., Belman, N. D., Boccia, R. V., Hurwitz, H., . . . Rosen, L. S. (2011). The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. WoS1 |
| 2011 | Jain, K., Beeke, C., Price, T., Young, G., Roder, D., Padbury, R., . . . Karapetis, C. (2011). A population-based study of metastatic colorectal cancer (mCRC) in people age 80 and older: Findings from the South Australian Clinical Registry (SACR) for mCRC.. J Clin Oncol, 29(4_suppl), 514. |
| 2011 | Bishnoi, S., Pittman, K., Yeend, S., Brown, M., Koczwara, B., Kotasek, D., . . . Price, T. (2011). Gemcitabine and carboplatin in carcinoma of unknown primary site (CUP) in elderly patients: Analysis of a phase 2 Adelaide Cancer Trials and Education Collaborative (ACTEC) study. Journal of Geriatric Oncology, 2(4), 233-238. Scopus1 WoS1 |
| 2011 | Bishnoi, S., Pittman, K., Colbeck, M., Townsend, A., Hardingham, J., Sukumaran, S., . . . Price, T. (2011). Small cell lung cancer: Patterns of care and their influence on survival - 25 years experience of a single Australian oncology unit. Asia Pacific Journal of Clinical Oncology, 7(3), 252-257. Scopus7 WoS7 Europe PMC5 |
| 2011 | Kotasek, D., Tebbutt, N., Desai, J., Welch, S., Siu, L., McCoy, S., . . . Price, T. (2011). Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer, 11(1), 313-1-313-13. Scopus9 WoS8 Europe PMC8 |
| 2011 | Tebbutt, N., Murphy, F., Zannino, D., Wilson, K., Cummins, M., Abdi, E., . . . Price, T. (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. Scopus42 WoS36 Europe PMC33 |
| 2011 | Price, T., Hardingham, J., Lee, C., Weickhardt, A., Townsend, A., Wrin, J., . . . Tebbutt, N. (2011). Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX Trial of capecitabine alone or in combination with Bevacizumab and Mitomycin in advanced colorectal cancer. Journal of Clinical Oncology, 29(19), 2675-2682. Scopus191 WoS192 Europe PMC162 |
| 2011 | Neo, E., Beeke, C., Price, T., Maddern, G., Karapetis, C., Luke, C., . . . Padbury, R. (2011). South Australian clinical registry for metastatic colorectal cancer. Australian and New Zealand Journal of Surgery, 81(5), 352-357. Scopus48 WoS45 Europe PMC47 |
| 2011 | Haller, D., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., . . . Schmoll, H. (2011). Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. Journal of Clinical Oncology, 29(11), 1465-1471. Scopus717 WoS636 Europe PMC517 |
| 2011 | Arentz, G., Chataway, T., Price, T., Izwan, Z., Hardi, G., Cummins, A., & Hardingham, J. (2011). Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. Clinical Proteomics, 8(1), 16:1-16:13. Scopus39 Europe PMC29 |
| 2011 | Townsend, A. R., Broadbridge, V., Beeke, C., Karapetis, C. S., Bishnoi, S., Jain, K., . . . Price, T. J. (2011). Rechallenge with oxaliplatin and fluoropyrimidine (FOX) after prior therapy in metastatic colorectal carcinoma (mCRC). JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. |
| 2011 | Karapetis, C. S., Townsend, A., Beeke, C., Bishnoi, S., Kunal, J., Luke, C., . . . Price, T. J. (2011). Impact of watching prior to commencement of chemotherapy for metastatic colorectal cancer (mCRC): Findings from the South Australian Clinical Registry (SACR) for mCRC. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. |
| 2011 | Jain, K., Price, T. J., Beeke, C., Padbury, R., Young, G. P., Roder, D., . . . Karapetis, C. S. (2011). An analysis of the effect of stage at diagnosis of bowel cancer on survival: Findings from the South Australian Clinical Registry (SACR) for metastatic colorectal cancer (mCRC).. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. |
| 2011 | Jain, K., Beeke, C., Price, T. J., Young, G. P., Roder, D., Padbury, R., . . . Karapetis, C. S. (2011). A population-based study of metastatic colorectal cancer (mCRC) in people age 80 and older: Findings from the South Australian Clinical Registry (SACR) for mCRC. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page. |
| 2011 | Townsend, A. R., Pirc, L., Hardingham, J., Karapetis, C. S., Tebbutt, N. C., Singhal, N., & Price, T. J. (2011). A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page. |
| 2011 | Luke, C., Sargent, N., Pittman, K., Price, T., & Roder, D. (2011). Epidemiology of cancers of the kidney in an Australian population. Asian Pacific journal of cancer prevention, 12(11), 2893-2899. Scopus13 WoS12 Europe PMC11 |
| 2010 | Broadbridge, V., Townsend, A., Pittman, K., Kimber, R., Patterson, W., Sukumaran, S., & Price, T. J. (2010). Reversing Hyperammonemia in Neuroendocrine Tumors. Journal of Clinical Gastroenterology, 44(8), e186-e189. Scopus7 WoS5 Europe PMC6 |
| 2010 | Sukumaran, S., Pittman, K., Patterson, W., Dickson, J., Yeend, S., Townsend, A., . . . Price, T. (2010). A phase I study to determine the safety, tolerability and maximum tolerated dose of green-lipped mussel (Perna canaliculus) lipid extract, in patients with advanced prostate and breast cancer. Annals of Oncology, 21(5), 1089-1093. Scopus10 WoS8 Europe PMC7 |
| 2010 | Price, T. J., Townsend, A. R., & Khattak, A. (2010). Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: Results of a randomised phase II study. Annals of Oncology, 21(10), 2121. Europe PMC1 |
| 2010 | Price, T. J., Sobrero, A. F., Wilson, G., Van Cutsem, E., Aleknaviciene, B., Zaniboni, A., . . . Peeters, M. (2010). Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). JOURNAL OF CLINICAL ONCOLOGY, 28(15), 2 pages. |
| 2010 | Townsend, A., Price, T., Yeend, S., Pittman, K., Patterson, K., & Luke, C. (2010). Metastatic carcinoid tumor: changing patterns of care over two decades. Journal of Clinical Gastroenterology, 44(3), 195-199. Scopus22 WoS19 Europe PMC15 |
| 2010 | Peeters, M., Price, T., Cervantes, A., Sobrero, A., Ducreux, M., Hotko, Y., . . . Gansert, J. (2010). Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28(31), 4706-4713. Scopus913 WoS829 Europe PMC677 |
| 2010 | Luke, C., Price, T., Townsend, A., Karapetis, C., Kotasek, D., Singhal, N., . . . Roder, D. (2010). Epidemiology of neuroendocrine cancers in an Australian population. Cancer Causes & Control, 21(6), 931-938. Scopus37 WoS31 Europe PMC23 |
| 2010 | Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., . . . Price, T. (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX study. Journal of Clinical Oncology, 28(19), 3191-3198. Scopus379 WoS360 Europe PMC308 |
| 2010 | Price, T., Tebbutt, N., Karapetis, C., Segelov, E., Pavlakis, N., Cunningham, D., . . . Shapiro, J. (2010). Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: Report from the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 9(1), 8-14. Scopus9 WoS9 Europe PMC5 |
| 2010 | Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., & Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal, 40(6), 453-458. Scopus5 WoS4 Europe PMC4 |
| 2010 | Luke, C., Price, T., & Roder, D. (2010). Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population. Asian Pacific Journal of Cancer Prevention, 11(6), 1479-1485. Scopus22 WoS16 Europe PMC12 |
| 2010 | Haller, D. G., Cassidy, J., Tabernero, J., Maroun, J. A., De Braud, F. G., Price, T. J., . . . Schmoll, H. (2010). Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for state III colon cancer (NO16968): Impact of age on disease-free survival (DFS). JOURNAL OF CLINICAL ONCOLOGY, 28(15), 2 pages. WoS4 |
| 2010 | Schofield, P., Stockler, M., Zannino, D., Wong, N., Ransom, D., Moylan, E., . . . Jefford, M. (2010). Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. |
| 2010 | Stockler, M., Zannino, D., Wilson, K., Gebski, V., Abdi, E. A., Strickland, A., . . . Tebbutt, N. C. (2010). Patient-rated outcomes (PRO) in a randomized trial of first-line chemotherapy with capecitabine (C), bevacizumab (B), and mitomycin-C (M) for metastatic colorectal cancer: The AGITG MAX trial. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. |
| 2010 | Weickhardt, A. J., Price, T. J., Pavlakis, N., Skrinos, E., Dobrovic, A., Salemi, R., . . . Tebbutt, N. C. (2010). DUX study A phase 11 study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page. |
| 2010 | Chua, Y. J., Michael, M., Zalcberg, J. R., Hicks, R. J., Goldstein, D., Liauw, W., & Price, T. (2010). Antitumor effect of somatostatin analogs in neuroendocrine tumors. Journal of Clinical Oncology, 28(3), e41-e42. Scopus8 WoS6 Europe PMC3 |
| 2009 | Herbertson, R. A., Karapetis, C., Price, T., Tebbutt, N., & Pavlakis, N. (2009). Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews, (4). Scopus7 |
| 2009 | Peeters, M., Price, T., & Van Laethem, J. L. (2009). Erratum: Anti epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: Where are we today? (The Oncologist (2009) 14 (29-39)). Oncologist, 14(3), 307. Scopus2 |
| 2009 | Townsend, A., Price, T., & Karapetis, C. (2009). Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database of Systematic Reviews, 2009(4), 16 pages. Scopus27 WoS20 Europe PMC16 |
| 2009 | Michael, M., Price, T., Ngan, S. Y., Ganju, V., Strickland, A. H., Muller, A., . . . Leong, T. (2009). A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. British Journal of Cancer, 100(1), 37-43. Scopus5 WoS4 Europe PMC4 |
| 2009 | Sukumaran, S., Pavlakis, N., Pittman, K., Patterson, K., & Price, T. (2009). Capecitabine and irinotecan (XELIRI) in first-line treatment of metastatic colorectal cancer (mCRC): A systematic review of controlled clinical trials.. J Clin Oncol, 27(15_suppl), e15100. |
| 2009 | Tebbutt, N. C., Gebski, V., Wilson, K., Cummins, M., Chua, Y., Robinson, B., . . . Price, T. (2009). International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial.. J Clin Oncol, 27(15_suppl), 4023. |
| 2009 | Luke, C., Price, T., Karapetis, C., Singhal, N., & Roder, D. (2009). Pancreatic cancer epidemiology and survival in an Australian population. Asian Pacific Journal of Cancer Prevention, 10(3), 369-374. Scopus16 WoS16 Europe PMC12 |
| 2009 | Peeters, M., Price, T., & Van Laethem, J. (2009). Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?. The Oncologist, 14(1), 29-39. Scopus68 WoS67 Europe PMC57 |
| 2009 | Mushtaq, U., Price, T., Laddipeerla, N., Townsend, A., & Broadbridge, V. (2009). Contrast induced hyperthyroidism due to iodine excess.. BMJ case reports, 2009, bcr06.2009.1982. Europe PMC4 |
| 2008 | Kichenadasse, G., Townsend, A. R., Pittman, K. B., Patterson, K., Stephens, J. H., Borg, M., . . . Price, T. J. (2008). Rectal cancer: Pattern of care in the elderly. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. |
| 2008 | Nott, L., Price, T. J., Pittman, K., Patterson, K., Young, R., & Fletcher, J. (2008). Hyperammonaemic encephalopathy associated with rituximab-containing chemotherapy.. Internal Medicine Journal, 38(10), 800-803. |
| 2008 | Townsend, A. R., Yeend, S., Luke, C., Pittman, K. B., Patterson, K., & Price, T. J. (2008). Metastatic carcinoid tumour (MCT): 20 years experience at the Queen Elizabeth Hospital. Does management by a medical oncology unit (MOU) improve outcome?. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. |
| 2008 | Kotasek, D., Tebbutt, N. C., Welch, S., Wagner, V., McCoy, S., Sun, Y., & Price, T. J. (2008). Safety and pharmacokinetics (PK) of motesanib diphosphate in combination with gemcitabine (G) and erlotinib (E) for the treatment of patients (pts) with solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. WoS4 |
| 2008 | Townsend, A., Price, T., Patterson, K., & Pittman, K. (2008). Fluorouracil-induced Hepatic Artery Spasm Preventing Yttrium-90 Microsphere Administration. Clinical Nuclear Medicine, 33(8), 528-530. Scopus2 WoS2 Europe PMC2 |
| 2008 | Price, T., Lipton, L., McGreivy, J., McCoy, S., Sun, Y., & Rosenthal, M. (2008). Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. British Journal of Cancer, 99(9), 1387-1394. Scopus16 WoS16 Europe PMC14 |
| 2008 | Lewis, K., Robinson, W., Millward, M., Powell, A., Price, T., Thomson, D., . . . Gonzalez, R. (2008). A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Investigational New Drugs, 26(1), 89-94. Scopus74 WoS73 Europe PMC64 |
| 2008 | Nott, L., Price, T., Patterson, K., Young, R., & Fletcher, J. (2008). Hyperammonaemic encephalopathy associated with rituximab-containing chemotherapy. Internal Medicine Journal, 38(10), 800-803. Scopus11 WoS7 Europe PMC7 |
| 2008 | Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., . . . Zalcberg, J. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine, 359(17), 1757-1765. Scopus3366 WoS3057 Europe PMC2566 |
| 2008 | Price, T., Pittman, K., Patterson, W., Colbeck, M., Rieger, N., Hewett, P., . . . Roder, D. (2008). Management and survival trends in advanced colorectal cancer. Clinical Oncology, 20(8), 626-630. Scopus8 WoS10 Europe PMC7 |
| 2008 | Luke, C., Koczwara, B., Karapetis, C., Pittman, K., Price, T., Kotasek, D., . . . Roder, D. (2008). Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Australian and New Zealand Journal of Public Health, 32(4), 383-389. Scopus30 WoS31 Europe PMC26 |
| 2008 | Price, T. J., & Townsend, A. (2008). Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Archives of Surgery, 143(3), 313-314. Scopus7 WoS7 Europe PMC7 |
| 2008 | Price, T. J., Gebski, V., van Hazel, G. A., Robinson, B. A., Broad, A., Ganju, V., . . . Tebbutt, N. C. (2008). International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. |
| 2008 | Price, T. J., & Nott, L. (2008). Unusual hair changes with prolonged erlotinib exposure. Internal Medicine Journal, 38(10), 807. Scopus1 WoS1 Europe PMC1 |
| 2008 | Stockler, M. R., Grimison, P. S., Price, T. J., van Hazel, G. A., Robinson, B. A., Broad, A., . . . Tebbutt, N. C. (2008). Comparing utilities for advanced colorectal cancer valued from societal and cancer patients' perspectives using baseline data from the MAX study. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. |
| 2008 | Townsend, A., Price, T., & Karapetis, C. (2008). Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database of Systematic Reviews, (2). Scopus2 |
| 2008 | Herbertson, R. A., Karapetis, C., Pavlakis, N., Price, T., & Tebbutt, N. (2008). Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews, (2). Scopus71 |
| 2007 | Schmoll, H., Cartwright, T., Tabernero, J., Nowacki, M., Figer, A., Maroun, J., . . . Haller, D. (2007). Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1 864 patients. Journal of Clinical Oncology, 25(1), 102-109. Scopus292 WoS250 Europe PMC197 |
| 2007 | Nott, L., Yeend, S., Pirc, L., Pittman, K., Patterson, K., & Price, T. (2007). Successfully improving access and accrual to oncology clinical trials. Cancer, 109(8), 1451-1453. Scopus3 WoS3 Europe PMC3 |
| 2007 | Luke, C., Gill, P., Birrell, S., Humeniuk, V., Borg, M., Karapetis, C., . . . Roder, D. (2007). Treatment and survival from breast cancer: The experience of patients at South Australian teaching hospitals between 1977 and 2003. Journal of Evaluation in Clinical Practice, 13(2), 212-220. Scopus7 WoS7 Europe PMC6 |
| 2007 | Kichenadasse, G., Zakaria, J., Rodda, D., Hewett, P., Rieger, N., Stephens, J., . . . Price, T. (2007). Squamous cell carcinoma of the anal canal at the Queen Elizabeth Hospital: A local experience. Asia Pacific Journal of Clinical Oncology, 3(4), 214-218. Scopus3 WoS3 |
| 2007 | Jonker, D., O'Callaghan, C., Karapetis, C., Zalcberg, J., Tu, D., Au, H., . . . Moore, M. (2007). Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine, 357(20), 2040-2048. Scopus1855 WoS1685 Europe PMC1370 |
| 2007 | Nott, L., Price, T., Pittman, K., Patterson, K., & Fletcher, J. (2007). Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapy. Leukemia & Lymphoma, 48(9), 1702-1711. Scopus96 WoS86 Europe PMC65 |
| 2006 | Pittman, K., Olver, I., Koczwara, B., Kotasek, D., Patterson, W., Keefe, D., . . . Price, T. (2006). Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. British Journal of Cancer, 95(10), 1309-1313. Scopus32 WoS30 Europe PMC26 |
| 2005 | Luke, C., Koczwara, B., Moore, J., Olver, I., Penniment, M., Pittman, K., . . . Roder, D. (2005). Treatment and survival from colorectal cancer: The experience of patients at South Australian teaching hospitals between 1980 and 2002. Clinical Oncology, 17(5), 372-381. Scopus14 WoS12 Europe PMC10 |
| 2005 | Chong, G., Dickson, J. L. B., Cunningham, D., Norman, A. R., Rao, S., Hill, M. E., . . . Tebbutt, N. (2005). Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. British Journal of Cancer, 93(5), 510-514. Scopus61 WoS59 Europe PMC41 |
| 2005 | Schmoll, H., Tabernero, J., Nowacki, M., Maroun, J., Price, T., Lim, R., . . . Haller, D. (2005). Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. EJC SUPPLEMENTS, 3(2), 174. |
| 2005 | Leong, T., Michael, M., Ganju, V., Price, T., Strickland, A., Jefford, M., . . . Zalcberg, J. (2005). Phase I trial of capecitabine and gemcitabine with concurrent radical radiotherapy in locally advanced pancreatic cancer: interim results. EJC SUPPLEMENTS, 3(2), 222. |
| 2004 | Price, T. J., Ross, P. J., Hickish, T., Tait, D., Norman, A. R., Ford, H. E. R., . . . Cunningham, D. (2004). Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clinical Colorectal Cancer, 3(4), 235-242. Scopus33 Europe PMC23 |
| 2004 | Bardy, P., Sage, E., Norman, J., Chunilal, S., Dart, G., Pittman, K., . . . Roder, D. (2004). Reasons for lower survival from non-hodgkin's lymphoma among older patients. Asian Pacific Journal of Cancer Prevention, 5(3), 301-307. |
| 2004 | Rao, S., Cunningham, D., Price, T., Hill, M., Ross, P., Tebbutt, N., . . . Shellito, P. (2004). Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. British Journal of Cancer, 91(5), 839-843. Scopus35 WoS34 Europe PMC21 |
| 2003 | Mackay, H. J., Hill, M., Twelves, C., Glasspool, R., Price, T., Campbell, S., . . . Cunningham, D. (2003). A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. Annals of Oncology, 14(8), 1264-1269. Scopus21 WoS22 Europe PMC19 |
| 2002 | Price, T., Karapetis, C., Chevalier, V., Curé, H., Chollet, P., & Lévi, F. (2002). Chronomodulated chemotherapy in advanced colorectal carcinoma [7] (multiple letters). Journal of Clinical Oncology, 20(18), 3937-3939. Scopus1 |
| 2002 | Price, T., Hill, M., Norman, A., Sumpter, K., & Cunningham, D. (2002). The Royal Marsden experience of the use of carboplatin in oesophageal carcinoma. Gastrointestinal Oncology, 4(1), 23-26. Scopus3 |
| 2002 | Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., . . . Norman, A. (2002). Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. Journal of Clinical Oncology, 20(8), 1996-2004. Scopus492 WoS404 Europe PMC328 |
| 2000 | Price, T., & Hill, M. (2000). UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. Oncology, 14(10 SUPPL. 9), 28-31. Scopus10 WoS7 Europe PMC4 |
| 2000 | Hill, M., Mackay, H., Cunningham, D., Glasspool, R., Price, T., Campbell, S., . . . Twelves, C. (2000). Phase I/II study of oral uracil/tegafur (UFT®), leucovorin and irinotecan in patients with advanced colorectal cancer.. ANNALS OF ONCOLOGY, 11, 45. WoS6 |
| 2000 | Price, T., Walton, M., Cunningham, D., & Workman, P. (2000). Activity of paullones in colon cell lines does not correlate to cell cycle protein expression.. ANNALS OF ONCOLOGY, 11, 13. WoS1 |
| 2000 | Zuha, R., Price, T., Powles, R., & Treleaven, J. (2000). Paradoxical emboli after central venous catheter removal. Annals of Oncology, 11(7), 885-886. Scopus22 WoS17 Europe PMC17 |
| 2000 | Ford, H. E. R., Cunningham, D., Ross, P. J., Rao, S., Aherne, G. W., Benepal, T. S., . . . Gruia, G. (2000). Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. British Journal of Cancer, 83(2), 146-152. Scopus24 WoS20 Europe PMC14 |
| 2000 | Price, T., Walton, M. I., Titley, J., Cunningham, D., & Workman, P. (2000). Studies on the mechanism of action of the cyclin dependent kinase inhibitors 9-nitro and 10-bromopaullone in human colon tumour cell lines.. CLINICAL CANCER RESEARCH, 6, 4530S. |
| 2000 | Massacesi, C., Norman, A., Price, T., Hill, M., Ross, P., & Cunningham, D. (2000). A clinical nomogram for predicting long-term survival in advanced colorectal cancer. European Journal of Cancer, 36(16), 2044-2052. Scopus46 WoS41 Europe PMC35 |
| 1999 | Castagnola, E., Viscoli, C., Olver, I. N., Price, T. J., & Patterson, W. K. (1999). Rifampicin as treatment for pruritus in malignant cholestasis: An example of an improper indication for anti-infective drugs (multiple letters). Supportive Care in Cancer, 7(3), 160. Scopus2 Europe PMC1 |
| 1998 | Price, T. J., Patterson, W. K., & Olver, I. N. (1998). Rifampicin as treatment for pruritus in malignant cholestasis. Supportive Care in Cancer, 6(6), 533-535. Scopus19 WoS19 Europe PMC11 |
| - | Mikaeel, R. R., Price, T. J., Smith, E., Drew, P. A., Uylaki, W., Horsnell, M., & Young, J. P. (2019). Colorectal Cancer in Australian Young Adults. Mathews Journal of Cancer Science, 4(1). |
| - | Song, R., Mikaeel, R. R., He, Z., Horsnell, M., Uylaki, W., Meng, W., . . . Fan, X. (2025). Identification of Novel Susceptibility Genes for Early-Onset Colorectal Cancer Through Germline Rare Variant Burden Testing. Cancers, 17(24), 3931. |
| Year | Citation |
|---|---|
| 2016 | Lo, L., Young, J., Price, T., & Townsend, A. (2016). BRAF Mutation in Colorectal Cancer. In L. Rodrigo (Ed.), Colorectal Cancer-From pathogenesis to treatment (pp. 89-117). Online: INTECH. |
| 2014 | Savas, P., & Price, T. (2014). Medical oncology. In M. Wichmann, & G. Maddern (Eds.), Palliative Surgery (Vol. 9783642537097, pp. 71-82). Germany: Springer. DOI Scopus1 |
| 2012 | Hardingham., Wrin, J., Shivasami, A., Tebbutt, N., & Price, T. (2012). BRAF V600E Mutation Detection Using High Resolution Probe Melting Analysis. In P. Hernandez-Rodriguez, & A. Gomez (Eds.), Polymerase Chain Reaction (pp. 143-156). Online: InTech. |
| Year | Citation |
|---|---|
| 2025 | Dean, A. P., Sjoquist, K., Gebski, V., Karapetis, C. S., Lomma, C., Burge, M. E., . . . Price, T. J. (2025). AGITG ASCEND: Randomised, double-blind phase II study of certepetide or placebo added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma: Initial results. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 728). CA, San Francisco: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2023 | Vasconcelos, J. P. S., Chen, N., Tu, D., Brule, S. Y., Goodwin, R. A., Jonker, D. J., . . . Loree, J. M. (2023). Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 124). CA, San Francisco: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2023 | Day, D., Starus, A., Gebski, V., Simes, J., Hayes, T., Padinharakam, S., . . . Segelov, E. (2023). Minimal residual disease (MRD) detection using a tumour naive circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. In ANNALS OF ONCOLOGY Vol. 34 (pp. S426-S427). SPAIN, Madrid: ELSEVIER. DOI WoS2 |
| 2022 | Bob, T. L., Velcheti, V., Price, T. J., Hong, D. S., Fakih, M., Kim, D. -W., . . . Skoulidis, F. (2022). Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS17 |
| 2022 | Price, T. J. (2022). International trial activity of AGITG. In ANNALS OF ONCOLOGY Vol. 33 (pp. S406). JAPAN, Kyoto: ELSEVIER. DOI |
| 2022 | Price, T., Grewal, J., Abed, A., Moore, M., Yeh, Y. -M., Gadgeel, S., . . . Millward, M. (2022). A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRAS<SUP>G12C</SUP> inhibitor, in patients with advanced or metastatic solid tumor harboring KRAS<SUP>G12C</SUP> mutation.. In CANCER RESEARCH Vol. 82 (pp. 2 pages). LA, New Orleans: AMER ASSOC CANCER RESEARCH. WoS3 |
| 2022 | Prenen, H., Fakih, M., Falchook, G., Strickler, J., Hindoyan, A., Anderson, A., . . . Price, T. (2022). Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100. In ANNALS OF ONCOLOGY Vol. 33 (pp. S373). SPAIN, Barcelona: ELSEVIER. DOI WoS6 |
| 2022 | Wyrwicz, L., Taieb, J., Price, T., Bachet, J., Karthaus, M., Vidot, L., . . . Heinemann, V. (2022). Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies. In ANNALS OF ONCOLOGY Vol. 33 (pp. S364). SPAIN, Barcelona: ELSEVIER. DOI |
| 2022 | Jungels, C., Kotecki, N., Calvo, E., Garralda, E., Price, T., Zahn, X., . . . Legrande, J. (2022). Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors.. In CANCER RESEARCH Vol. 82 (pp. 1 page). LA, New Orleans: AMER ASSOC CANCER RESEARCH. |
| 2022 | Siu, D., Gormly, K., Espinoza, D., Hague, W., Jeffery, M., Price, T., . . . Jameson, M. (2022). Progress and challenges for AGITG spar - A randomised phase II trial of preoperative chemoradiation with simvastatin for rectal cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 48). WILEY. |
| 2022 | Hsu, K., Karapetis, C., Bright, T., Tomita, Y., Singhal, N., Gowda, R., . . . Roy, A. (2022). Feasibility study of adjuvant chemotherapy in patients with oesophageal adenocarcinoma following neoadjuvant treatment: Results of the ACES trial. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 38-39). WILEY. |
| 2021 | Desai, J., Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Grothey, A., . . . Tabernero, J. (2021). Molecular correlates of clinical benefit in previously treated patients (pts) with <i>BRAF</i> V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 89). WILEY. |
| 2021 | Gormly, K., Espinoza, D., Hague, W., Jeffrey, M., Price, T., Karapetis, C., . . . Ackland, S. (2021). SPAR: Randomised phase II study of chemoradiation with or without simvastatin as preoperative treatment for rectal cancer (an AGITG trial). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 36). WILEY. |
| 2021 | Li, B., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G., . . . Wolf, J. (2021). Registrational Phase 2 Trial of Sotorasib in <i>KRAS</i> p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis. In JOURNAL OF THORACIC ONCOLOGY Vol. 16 (pp. S61). ELSEVIER SCIENCE INC. WoS27 |
| 2021 | Skoulidis, F., Schuler, M., Wolf, J., Barlesi, F., Price, T., Dy, G., . . . Velcheti, V. (2021). Genomic Profiles and Potential Determinants of Response and Resistance in <i>KRAS</i> p.G12C-mutated NSCLC Treated With Sotorasib. In JOURNAL OF THORACIC ONCOLOGY Vol. 16 (pp. S929-S930). ELSEVIER SCIENCE INC. WoS1 |
| 2021 | Schuler, M., Li, B. T., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., . . . Wolf, J. (2021). Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis. In PNEUMOLOGIE Vol. 75 (pp. S38). GEORG THIEME VERLAG KG. DOI |
| 2021 | Taieb, J., Price, T., Wyrwicz, L., Vidot, L., Raimond-Thibaut, A., Chrostek, H., . . . Falcone, A. (2021). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study. In ANNALS OF ONCOLOGY Vol. 32 (pp. S210). ELECTR NETWORK: ELSEVIER. DOI WoS2 |
| 2021 | Cummins, M., Leyden, S., Pavlakis, N., Chan, D., Michael, M., Hicks, R., . . . Stell, A. (2021). Optimal PLAnning of treatment and research of neuroendocrine tumours (NETs) in Australia: The PLANET registry and patient-reported outcomes via PLANET App. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 169-170). WILEY. |
| 2021 | Desai, J., Kopetz, S., Aderka, D., Grothey, A., Van Cutsem, E., Yaeger, R., . . . Tabernero, J. (2021). Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for <i>BRAF</i> V600E-mutant metastatic colorectal cancer (mCRC). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 119-120). WILEY. |
| 2020 | Chiu, C. -F., Yeh, Y. -M., Yeh, K. -H., Desai, J., Price, T. J., Tebbutt, N., . . . Kopetz, S. (2020). Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study). In ANNALS OF ONCOLOGY Vol. 31 (pp. S1276). ELECTR NETWORK: ELSEVIER. DOI WoS1 |
| 2020 | Price, T., Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H. S., . . . Tabernero, J. (2020). Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 128). WILEY. |
| 2020 | Price, T., Chawla, S., Falchook, G., Prenen, H., Lugowska, I., Subbiah, V., . . . Sadraei, N. (2020). EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 8 (pp. A245). BMJ PUBLISHING GROUP. DOI |
| 2020 | Yong, C., Holden, C., Buckley, E., Poprawski, D., Turnbull, D., Ratcliffe, J., . . . Price, T. (2020). Age of uncertainty: The management of older patients diagnosed with colorectal cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 132). WILEY. |
| 2020 | Buckley, E., Holden, C., Poprawski, D., Singal, N., Turnbull, D., Roder, D., . . . Price, T. (2020). Variation in colorectal cancer MDT, treatment and survival outcomes: A population-based linked data study in South Australia (SA). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 90). WILEY. |
| 2020 | Strickler, J., Fakih, M., Price, T., Desai, J., Durm, G., Krauss, J., . . . Hong, D. (2020). AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial. In ANNALS OF ONCOLOGY Vol. 31 (pp. S226). ELECTR NETWORK: ELSEVIER. DOI WoS1 |
| 2020 | Loupakis, F., Peeters, M., Geissler, M., Modest, D., Valladares-Ayerbes, M., Price, T., . . . Taieb, J. (2020). Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies. In ANNALS OF ONCOLOGY Vol. 31 (pp. S114-S115). ELECTR NETWORK: ELSEVIER. DOI |
| 2020 | Fakih, M., Desai, J., Kuboki, Y., Strickler, J. H., Price, T. J., Durm, G. A., . . . Hong, D. S. (2020). CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS<SUP>G12C</SUP>, in patients with advanced colorectal cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. WoS18 |
| 2020 | Young, J. P., Horsnell, M. E., Uylaki, W., Mikaeel, R. R., Townsend, A., Poplawski, N., & Price, T. J. (2020). RELATIONSHIP BETWEEN GERMLINE MUTATION, PHENOTYPE AND FAMILY HISTORY IN YOUNG ONSET COLORECTAL CANCER. In GASTROENTEROLOGY Vol. 158 (pp. S1023). Austin, TX: W B SAUNDERS CO-ELSEVIER INC. |
| 2019 | Govindan, R., Fakih, M., Price, T., Falchook, G., Desai, J., Kuo, J., . . . Hong, D. (2019). Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRAS<SUP>G12C</SUP> Inhibitor, in Patients with Non-Small Cell Lung Cancer. In JOURNAL OF THORACIC ONCOLOGY Vol. 14 (pp. S1125-S1126). ELSEVIER SCIENCE INC. WoS2 |
| 2019 | Govindan, R., Fakih, M., Price, T., Falchook, G., Desai, J., Kuo, J., . . . Hong, D. (2019). Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRAS<SUP>G12C</SUP> Inhibitor, Evaluated in NSCLC. In JOURNAL OF THORACIC ONCOLOGY Vol. 14 (pp. S208). ELSEVIER SCIENCE INC. DOI WoS23 |
| 2019 | Desai, J., Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., . . . Tabernero, J. (2019). BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 15 (pp. 99). WILEY. |
| 2019 | Govindan, R., Fakih, M. G., Price, T. J., Falchook, G. S., Desai, J., Kuo, J. C., . . . Hong, D. S. (2019). Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours. In ANNALS OF ONCOLOGY Vol. 30 (pp. 163-+). Barcelona, SPAIN: OXFORD UNIV PRESS. WoS25 |
| 2019 | Loree, J. M., Dowers, A., Tu, D., O'Callaghan, C. J., Edelstein, D., Quinn, H., . . . Kopetz, S. (2019). Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2019 | Young, J. P., Symonds, E. L., Jesudason, D., Poplawski, N., Ruszkiewicz, A., Uylaki, W., . . . Price, T. J. (2019). INCREASED PREVALENCE OF TYPE 2 DIABETES IN YOUNG ONSET COLORECTAL CANCER. In GASTROENTEROLOGY Vol. 156 (pp. S676-S677). San Diego, CA: W B SAUNDERS CO-ELSEVIER INC. DOI |
| 2019 | Mikaeel, R., Symonds, E., Kimber, J., Uylaki, W., Horsnell, M., Rico, G., . . . Price, T. (2019). Personal history of type 2 diabetes is a potential risk marker for colorectal cancer in young people. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 34 (pp. 42). WILEY. |
| 2019 | Sartore-Bianchi, A., Peeters, M., Geissler, M., Taieb, J., Garcia-Alfonso, P., Price, T., . . . Koehne, C. -H. (2019). Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Kohne prognostic category: Retrospective analysis of the panitumumab (Pmab) PRIME study. In ANNALS OF ONCOLOGY Vol. 30 (pp. 216). Barcelona, SPAIN: OXFORD UNIV PRESS. |
| 2018 | Falcone, A., Taieb, J., Price, T. J., Seitz, J. F., Wyrwicz, L., Becquart, M., . . . Van Cutsem, E. (2018). Quality of life at baseline in the international open-label early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb). In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS2 |
| 2018 | Price, T. J., Taieb, J., Falcone, A., Seitz, J. F., Wyrwicz, L., Becquart, M., . . . Van Cutsem, E. (2018). Baseline characteristics in the international, open-label, early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2018 | Taniguchi, H., Yamanaka, T., Sakai, D., Yamazaki, K., Muro, K., Peeters, M., & Price, T. J. (2018). Panitumumab versus cetuximab in patients with wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2018 | Townsend, A. R., Asher, R., Price, T. J., Lee, C. K., Dorward, H., Gebski, V., . . . Hardingham, J. (2018). Single nucleotide polymorphisms (SNPs) in COL4A2, PPP1R17, and ARHGAPP44 and prognostic value in metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2018 | Clarke, S. J., Burge, M. E., Feeney, K., Jones, K., Gibbs, P., Molloy, M. P., . . . Tebbutt, N. C. (2018). The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2018 | Price, T. J., Karapetis, C. S., Joanne, Y., Roy, A., Padbury, R., Maddern, G., . . . Townsend, A. R. (2018). Outcomes for metastatic colorectal cancer (mCRC) based on microsatellite instability.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2018 | Price, T. J., Shen, L., Ma, B., Esser, R., Chen, W. -F., Gibbs, P., . . . Cheng, A. -L. (2018). Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab plus first-line (1L) FOLFOX or FOLFIRI in patients with <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2018 | Taniguchi, H., Yamanaka, T., Sakai, D., Yamazaki, K., Muro, K., Peeters, M., & Price, T. J. (2018). Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer. In Annals of oncology : official journal of the European Society for Medical Oncology Vol. 29 (pp. viii151). Munich, GERMANY: OXFORD UNIV PRESS. DOI |
| 2018 | Price, T. J., Cehic, G., Kirkwood, I., Maddern, G., Wachter, E. A., Sarson, D., . . . Neuhaus, S. J. (2018). A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumours using intralesional rose bengal disodium. In Annals of oncology : official journal of the European Society for Medical Oncology Vol. 29 (pp. viii478). Munich, GERMANY: OXFORD UNIV PRESS. DOI |
| 2018 | Price, T. J., Falcone, A., Chantrill, L., Horvath, L., Chua, Y. J., Burge, M., . . . Van Cutsem, E. (2018). Baseline Patient Characteristics in the International, Open-Label, Preconnect Study of Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer (PHASE-IIIB). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 71-72). WILEY. |
| 2018 | Shepshelovich, D., Townsend, A. R., Espin-Garcia, O., Latifovic, L., O'Callaghan, C. J., Jonker, D. J., . . . Liu, G. (2018). The Association of <i>FCGR2A</i> and <i>FCGR3A</i> polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2018 | Boedigheimer, M., Ang, A. L., Kim, T. W., Thomas, A., Gibbs, P., Ruff, P., . . . Price, T. (2018). Circulating tumor (ct)DNA mutations in <i>EGFR</i> pathway genes and clinical outcomes for patients with metastatic colorectal cancer (mCRC) treated with panitumumab from the ASPECCT study. In MOLECULAR CANCER THERAPEUTICS Vol. 17 (pp. 4 pages). AMER ASSOC CANCER RESEARCH. DOI |
| 2018 | Price, T. J., Shen, L., Ma, B., Esser, R., Chen, W. -F., Gibbs, P., . . . Cheng, A. -L. (2018). Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab plus first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY. DOI |
| 2017 | Li, M., Rico, G. T., Chan, D. L., Oatley, M., Roach, P., Bailey, D., . . . Pavlakis, N. (2017). Case Series: Prevention and Management of Carcinoid Crises in High-Risk Neuroendocrine Patients Undergoing Peptide Receptor Radioligand Therapy (PRRT). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 13 (pp. 127). WILEY. |
| 2017 | Michael, M., Liauw, W., McLachlan, S. -A., Link, E., Matera, A., Thompson, M., . . . Burge, M. E. (2017). The utility of genomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynannics: The PREDICT IR study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2017 | Price, T. J., Karapetis, C. S., Roy, A. C., Padbury, R., Maddern, G., Roder, D., . . . Townsend, A. R. (2017). Bevacizumab and its impact on survival for patients receiving subsequent anti-EGFR therapy: Results from the South Australian metastatic colorectal cancer registry.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2017 | Townsend, A. R., Hardingham, J., Tebbutt, N. C., Karapetis, C. S., Singhal, N., Joshi, R., . . . Price, T. J. (2017). A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2017 | Price, T. J., Peeters, M., Boedigheimer, M., Kim, T. W., Gibbs, P., Thomas, A. L., . . . Bach, B. A. (2017). Clinical outcomes and emergent circulating tumor (ct)DNA RAS mutations and allele fraction for patients with metastatic colorectal cancer (mCRC) treated with panitumumab from the ASPECCT study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 6 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2017 | Boedigheimer, M., Ang, A., Price, T. J., Peeters, M., Kim, T. W., Gibbs, P., . . . Bach, B. A. (2017). Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS3 |
| 2017 | Prasanna, T., Craft, P. S., Chua, Y. J., Karapetis, C. S., Gibbs, P., Wong, R., . . . Yip, D. (2017). The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS7 |
| 2016 | Price, T. J., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., . . . Peeters, M. (2016). Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., . . . Price, T. J. (2016). Efficacy of panitumumab vs cetuximab in patients with wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Sud, S., O'Callaghan, C. J., Karapetis, C. S., Jonker, C., Price, T. J., Tebbutt, N. C., . . . Goodwin, R. A. (2016). Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2016 | Kim, T. W., Price, T., Peeters, M., Thomas, A., Gibbs, P., Hool, K., . . . Bach, B. (2016). Evaluation of emergent circulating tumor (ct) DNA RAS mutations in patients with metastatic colorectal cancer (mCRC) treated with panitumumab (pmab) monotherapy from the ASPECCT study. In EUROPEAN JOURNAL OF CANCER Vol. 69 (pp. S13-S14). Munich, GERMANY: ELSEVIER SCI LTD. DOI WoS2 |
| 2016 | Cheng, A. -L., Cornelio, G., Shen, L., Price, T., Yang, T. -S., Chung, I. -J., . . . Lim, R. (2016). Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study. In ANNALS OF ONCOLOGY Vol. 27 (pp. 123-124). Barcelona, SPAIN: OXFORD UNIV PRESS. WoS1 |
| 2016 | Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., . . . Price, T. J. (2016). Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2016 | Sud, S., O'Callaghan, C. J., Jonker, C., Karapetis, C. S., Price, T. J., Tebbutt, N. C., . . . Goodwin, R. A. (2016). Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2016 | Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., . . . Price, T. J. (2016). Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Mann, K., Elez, E., . . . Shapiro, J. (2015). The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation - analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S726). Vienna, AUSTRIA: ELSEVIER SCI LTD. DOI WoS1 |
| 2015 | Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., . . . Murugappan, S. (2015). Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2015 | Price, T. J., Newhall, K., Peeters, M., Kim, T. W., Li, J., Cascinu, S., . . . Murugappan, S. (2015). Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Spencer, A., Harrison, S., Burrows, F., Mainwaring, P., Price, T., Millward, M. J., . . . Trikha, M. (2015). Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. WoS1 |
| 2015 | Peeters, M., Price, T. J., Kim, T. W., Li, J., Cascinu, S., Ruff, P., . . . Murugappan, S. (2015). Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Price, T. J., Newhall, K., Peeters, M., Kim, T. W., Li, J., Cascinu, S., . . . Murugappan, S. (2015). Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2015 | Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., . . . Murugappan, S. (2015). Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2015 | Price, T., Townsend, A., Beeke, C., Roder, D., Padbury, R., Maddern, G., . . . Karapetis, C. (2015). BRAF testing in the community setting; are we testing enough given the importance of BRAF mutation and the clinical implications?. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S388). Vienna, AUSTRIA: ELSEVIER SCI LTD. DOI |
| 2015 | Price, T., Pavlakis, N., Karapetis, C., Michael, M., Singhal, N., Goldstein, D., . . . Chua, Y. J. (2015). The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care. In NEUROENDOCRINOLOGY Vol. 102 (pp. 98). Barcelona, SPAIN: KARGER. |
| 2015 | Klevansky, M., Mislang, A. R. A., Kwatra, V., Griffiths, C. L., Hsieh, A. H. -C., Takhar, H., . . . Roy, A. (2015). FOLFIRINOX for advanced pancreato-biliary adenocarcinoma, a multi-centre retrospective analysis: The South Australian Experience. In ANNALS OF ONCOLOGY Vol. 26 (pp. 66). Singapore, SINGAPORE: OXFORD UNIV PRESS. WoS1 |
| 2015 | Mooi, J., Chong, G., Brown, S., Wong, R., Price, T. J., Skrinos, E., & Tebbutt, N. C. (2015). Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2015 | Sobrero, A. F., Price, T. J., Cervantes, A., Ducreux, M., Andre, T., Lordick, F., . . . Peeters, M. (2015). Quality of life (QoL) during second-line treatment with FOLFIRI plus /- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S369-S370). Vienna, AUSTRIA: ELSEVIER SCI LTD. DOI |
| 2015 | Patel, D., Lawrie, J., Cehic, G., Kitchener, M., Unger, S., Singhal, N., . . . Price, T. (2015). Outcome of peptide receptor radionuclide therapy with 177-Lu-octreotate in advanced neuroendocrine tumours (NET): South Australian sub study of the SIGNETURe Registry. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S413). Vienna, AUSTRIA: ELSEVIER SCI LTD. DOI WoS2 |
| 2015 | Cheng, A. -L., Cornelio, G. H., Shen, L., Price, T. J., Yang, T. -S., Chung, I. J., . . . Lim, R. S. C. (2015). Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Price, T., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., . . . Peeters, M. (2015). Efficacy outcomes by severity of skin toxicity from ASPECCT: Randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S366). Vienna, AUSTRIA: ELSEVIER SCI LTD. DOI |
| 2015 | Cheng, A. L., Cornelio, G. H., Shen, L., Price, T. J., Yang, T. S., Chung, I. J., . . . Lim, R. S. C. (2015). Association between early tumour shrinkage and outcomes in RAS-wild type patients with metastatic colorectal cancer receiving first-line FOLFOX or FOLFIRI plus cetuximab once every 2 weeks in the APEC study. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S367). Vienna, AUSTRIA: ELSEVIER SCI LTD. DOI |
| 2015 | Leyden, J., Khaswraw, M., Michael, M., Clarke, S., Pavlakis, N., & Price, T. J. (2015). NET CARE IN AUSTRALIA; THE PATIENT'S PERSPECTIVE OF THEIR NEUROENDOCRINE TUMOURS (NET) AND IMPACT OF DIAGNOSIS. In Asia-Pacific Journal of Clinical Oncology Vol. 11 (pp. 177). WILEY-BLACKWELL. |
| 2014 | Schmoll, H. -J., Haustermans, K., Price, T., Nordlinger, B., Hofheinz, R. D., Daisne, J. -F., . . . Van Cutsem, E. (2014). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis. In EUROPEAN JOURNAL OF CANCER Vol. 50 (pp. S6). ELSEVIER SCI LTD. DOI WoS4 |
| 2014 | Price, T., Peeters, M., Oliner, K., Cervantes, A., Sobrero, A., Ducreux, M., . . . Patterson, S. (2014). UPDATED ANALYSIS OF KRAS/NRAS AND BRAF MUTATIONS IN STUDY 20050181 OF PANITUMUMAB plus FOLFIRI FOR 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 10 (pp. 49-50). ASIA-PACIFIC: WILEY-BLACKWELL. |
| 2014 | Price, T. J., Beeke, C., Padbury, R., Roder, D., Townsend, A., Maddern, G., . . . Karapetis, C. S. (2014). DOES EXACT PRIMARY SITE IMPACT ON OUTCOME FOR METASTATIC COLORECTAL CANCER (MCRC)?. In ANNALS OF ONCOLOGY Vol. 25 (pp. 1 page). Madrid, SPAIN: OXFORD UNIV PRESS. |
| 2014 | Tomita, Y., Karapetis, C. S., Beeke, C., Padbury, R., Maddern, G., Roder, D., . . . Price, T. J. (2014). Survival outcomes for patients with metastatic colorectal cancer (mCRC) based on primary site, right (R) colon versus left (L) colon versus rectal (Rec) primary: Results from the South Australian Registry of mCRC.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS6 |
| 2014 | Vatandoust, S., Price, T. J., Padbury, R., Roder, D., Beeke, C., Roy, A., . . . Karapetls, C. S. (2014). Patterns of care and outcomes for young patients (age < 40) with metastatic colorectal cancer (mCRC): Findings from a population-based registry. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS3 |
| 2014 | Price, T. J., Bruhn, M., Lee, C., Hardingham, J., Townsend, A. R., Mann, K., . . . Tebbutt, N. C. (2014). Correlation of <i>PI3KCA</i>and extended <i>RAS</i> gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2014 | Charakidis, M., Price, T. J., Beeke, C., Padbury, R., Roder, D., Townsend, A. R., . . . Karapetis, C. S. (2014). Survival improvements associated with access to biologic agents: Results from the South Australian (SA) Metastatic Colorectal (mCRC) Registry. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2014 | Roohullah, A., Sjoquist, K. M., Gebski, V., Ng, W., Chua, W., Price, T. J., . . . Chantrill, L. A. (2014). The efficacy and safety outcomes of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the AGITG MAX clinical trial and in nontrial patients in two cancer centers.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2014 | Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., . . . Patterson, S. D. (2014). Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS4 |
| 2014 | Yeung, Y. H., Chionh, F. J. M., Price, T. J., Scott, A. M., Hoanh, T., Fang, G., . . . Tebbutt, N. C. (2014). Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS7 |
| 2014 | Schmoll, H. -J., Haustermans, K., Price, T. J., Nordlinger, B., Hofheinz, R., Daisne, J. -F., . . . Van Cutsem, E. (2014). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS75 |
| 2014 | Peeters, M., Oliner, K., Price, T., Cervantes, A., Sobrero, A., Ducreux, M., . . . Patterson, S. (2014). KRAS/NRAS AND BRAF MUTATIONS IN THE 20050181 STUDY OF PANITUMUMAB plus FOLFIRI FOR THE 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: UPDATED ANALYSIS. In ANNALS OF ONCOLOGY Vol. 25 (pp. 5). Barcelona, SPAIN: OXFORD UNIV PRESS. DOI WoS2 |
| 2014 | Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., . . . Patterson, S. D. (2014). Updated analysis of <i>KRAS</i>/<i>NRAS</i> and <i>BRAF</i> mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 2 pages). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS25 |
| 2014 | Chionh, F. J. M., Gebski, V., Chueh, A. C., Al-Obaidi, S. J., Welckhardt, A. J., Lee, C., . . . Tebbutt, N. C. (2014). Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (<i>VEGF</i>) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX Inter study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI |
| 2014 | Karapetis, C. S., Padman, S. J. -A., Beeke, C., Padbury, R., Kitchener, M., Kirkwood, I., . . . Price, T. J. (2014). The management of colorectal cancer (CRC) liver metastases with yttrium-90 microspheres (Y90): The south Australian (SA) experience.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2014 | Chan, K. K., Tu, D., O'Callaghan, C. J., Au, H. -J., Leighl, N. B., Brundage, M. D., . . . Mittmann, N. (2014). A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2014 | Chan, D., Pavlakis, N., Price, T. J., Karapetis, C. S., Tebbutt, N. C., Shapiro, J. D., & Segelov, E. (2014). Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS4 |
| 2014 | Chan, D., Segelov, E., Shapiro, J. D., Price, T. J., Karapetis, C. S., Tebbutt, N. C., & Pavlakis, N. (2014). Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2013 | Segelov, E., Wilson, K., Gebski, V., Waring, P. M., Tabernero, J., Wasan, H., . . . Shapiro, J. D. (2013). ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Patel, G. S., Ullah, S., Beeke, C., Hakendorf, P., Padbury, R., Price, T. J., & Karapetis, C. S. (2013). Association of body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) who received targeted therapies (TT). In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Price, T. J., Broadbridge, V., Beeke, C., Padbury, R., Maddern, G., Roder, D., & Karapetis, C. S. (2013). Outcomes of rural patients with metastatic colorectal cancer treated in a centralized system compared with their metropolitan counterparts. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Kumar, S. S., Price, T., & Hardingham, J. (2013). Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S493). Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. |
| 2013 | Kumar, S. S., Price, T., Mohyieldin, O., Borg, M., Townsend, A., & Hardingham, J. (2013). KRAS G13D mutations associated with sensitivity to cetuximab or panitumumab treatment in colorectal cancer cell lines. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S494). Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. |
| 2013 | Cheng, A. -L., Cornelio, G. H., Shen, L., Price, T. J., Yang, T. -S., Chung, I. -J., . . . Lim, R. S. C. (2013). Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with <i>KRAS</i> wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Tebbutt, N. C., Price, T. J., Sjoquist, K. M., Veillard, A. -S., Hall, M., Ferraro, D. A., . . . Gebski, V. (2013). Final results of AGITG ATTAX3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS3 |
| 2013 | Pavlakis, N., Goldstein, D., Sjoquist, K. M., Martin, A., Tsobanis, E., Yip, S., . . . O'Callaghan, C. J. (2013). INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)-A study by the Australasian Gastrointestinal Trials Group (AGITG). In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS1 |
| 2013 | Kumar, R., Beeke, C., Ullah, S., Price, T. J., Padbury, R., Roder, D., & Karapetis, C. S. (2013). Survival outcomes for patient with equivocal 18FDG-PET CT scan for extrahepatic disease prior to liver resection for metastatic colorectal cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Hocking, C., Karapetis, C., Beeke, C., Priest, K., Roder, D., Padbury, R., . . . Price, T. J. (2013). INDIGENOUS PATIENTS AND METASTATIC COLORECTAL CANCER: RESULTS FROM THE SOUTH AUSTRALIAN (SA) METASTATIC COLORECTAL CANCER (MCRC) REGISTRY. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 9 (pp. 132). WILEY-BLACKWELL. |
| 2013 | Schmoll, H. -J., Haustermans, K., Price, T. J., Nordlinger, B., Hofheinz, R., Daisne, J. -F., . . . Van Cutsem, E. (2013). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS26 |
| 2013 | Schmoll, H. J., Haustermans, K., Price, T., Nordlinger, B., Hofheinz, R. D., Daisne, J. F., . . . Van Cutsem, E. (2013). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Response to the local treatment after chemoradiation and surgery as secondary endpoint. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S482). Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. WoS4 |
| 2013 | Schmoll, H. -J., Price, T., Haustermanns, K., Nordlinger, B., Hofheinz, R. -D., Daisne, J. -F., . . . van Cutsem, E. (2013). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: Response to the local treatment after chemoradiation and surgery as secondary endpoint. In ONKOLOGIE Vol. 36 (pp. 103). KARGER. WoS1 |
| 2013 | Birrien, F., Castelle, B., Dailloux, D., Marieu, V., Rihouey, D., & Price, T. (2013). Video observation of megacusp evolution along a high-energy engineered sandy beach: Anglet, SW France. In JOURNAL OF COASTAL RESEARCH Vol. 165 (pp. 1727-1732). ENGLAND, Plymouth: COASTAL EDUCATION & RESEARCH FOUNDATION. DOI WoS14 |
| 2012 | Hahn, H. U., Keenan, A., Price, T., Borg, M., Thomas, H., Tucker, G., & Bardy, P. (2012). HEALTH OUTCOMES IN HODGKIN'S LYMPHOMA SURVIVORS: INCIDENCE OF LATE COMPLICATIONS WITH A FOCUS ON CARDIOVASCULAR DISEASE AND IMPACT OF SCREENING AND INTERVENTION. In HAEMATOLOGICA Vol. 97 (pp. 87). FERRATA STORTI FOUNDATION. |
| 2012 | Sobrero, A. F., Peeters, M., Price, T. J., Hotko, Y., Cervantes-Ruiperez, A., Ducreux, M., . . . Sidhu, R. (2012). Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY. DOI WoS4 |
| 2012 | Price, T. J., Beeke, C., Woodman, R., Karapetis, C. S., Kim, S., Maddern, G., . . . Padbury, R. (2012). Do patients with metastatic colorectal cancer (mCRC) with late relapse after curative surgery have a better survival?. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2012 | Schmoll, H. -J., Tabernero, J., Maroun, J. A., De Braud, F. G., Price, T. J., Van Cutsem, E., . . . Haller, D. G. (2012). Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY. DOI WoS9 |
| 2012 | Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., . . . Tebbutt, N. (2012). PTEN AND ADVANCED COLORECTAL CANCER (CRC): ANALYSIS FROM THE PHASE III AGITG MAX TRIAL OF CAPECITABINE ALONE OR IN COMBINATION WITH BEVACIZUMAB ± MITOMYCIN C. In ANNALS OF ONCOLOGY Vol. 23 (pp. 182). Vienna, AUSTRIA: OXFORD UNIV PRESS. |
| 2012 | Broadbridge, V. T., Hardingham, J., Pittman, K., Townsend, A., Colbeck, M., Hooper, B., & Price, T. (2012). ARE PATIENTS WITH RESECTABLE RECTAL CANCER BETTER OFF IN THE ERA OF MULTIDISCIPLINARY CARE?. In ANNALS OF ONCOLOGY Vol. 23 (pp. 208). Vienna, AUSTRIA: OXFORD UNIV PRESS. |
| 2012 | Siu, L. L., Shapiro, J. D., Jonker, D. J., Karapetis, C. S., Zalcberg, J. R., Simes, J., . . . O'Callaghan, C. J. (2012). Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, <i>K</i>-<i>RAS</i> wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. |
| 2012 | Schmoll, H. -J., Tabernero, J., Alfred Maroun, J., De Braud, F. G., Jay Price, T., Van Cutsem, E., . . . Haller, D. G. (2012). The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA). In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. WoS3 |
| 2012 | Sobrero, A. F., Peeters, M., Price, T. J., Hotko, Y., Cervantes-Ruiperez, A., Ducreux, M., . . . Sidhu, R. (2012). Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second -line treatment (tx) of metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. WoS1 |
| 2012 | Price, T., Wilson, K., Simes, R. J., Yip, D., Karapetis, C. S., Tebbutt, N. C., . . . Ransom, D. (2012). FINAL RESULTS OF AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP (AGITG) ARCTIC STUDY: AN INTERNATIONAL AUDIT OF RALTITREXED FOR PATIENTS WITH CARDIAC TOXICITY INDUCED BY FLUOROPYRIMIDINES (FP). In ANNALS OF ONCOLOGY Vol. 23 (pp. 178). Vienna, AUSTRIA: OXFORD UNIV PRESS. WoS1 |
| 2012 | Van Cutsem, E., Hamamoto, Y., Lee, J., Ohtsu, A., Qin, S., Price, T., . . . Doi, T. (2012). PROGNOSTIC FACTORS OF OVERALL SURVIVAL (OS) IN PREVIOUSLY TREATED ADVANCED GASTRIC CANCER (AGC): ANALYSIS OF THE PHASE 3 GRANITE-1 TRIAL. In ANNALS OF ONCOLOGY Vol. 23 (pp. 9). Barcelona, SPAIN: OXFORD UNIV PRESS. WoS1 |
| 2012 | Schmoll, H., Tabernero, J., Maroun, J. A., De Braud, F., Price, T., Van Cutsem, E., . . . Haller, D. (2012). TP, TS AND DPD AS POTENTIAL PREDICTORS OF OUTCOME FOLLOWING CAPECITABINE PLUS OXALIPLATIN (XELOX) VS. BOLUS 5-FLUOROURACIL/LEUCOVORIN (5-FU/LV) AS ADJUVANT THERAPY FOR STAGE III COLON CANCER: UPDATED BIOMARKER FINDINGS FROM STUDY NO16968 (XELOXA). In ANNALS OF ONCOLOGY Vol. 23 (pp. 187). Vienna, AUSTRIA: OXFORD UNIV PRESS. |
| 2012 | Douillard, J. -Y., Peeters, M., Rong, A., Siena, S., Braun, S., Sidhu, R., & Price, T. (2012). EFFECT OF POST-PROTOCOL ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MONOCLONAL ANTIBODY (MAB) THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH PANITUMUMAB (PMAB) PLUS CHEMOTHERAPY. In ANNALS OF ONCOLOGY Vol. 23 (pp. 194-195). Vienna, AUSTRIA: OXFORD UNIV PRESS. |
| 2012 | Douillard, J. -Y., Peeters, M., Rong, A., Siena, S., Braun, S., Sidhu, R., & Price, T. (2012). EFFECT OF POST-PROTOCOL ANTI-EGFR MAB THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH WILD-TYPE KRAS MCRC TREATED WITH PANITUMUMAB PLUS CHEMOTHERAPY. In ANNALS OF ONCOLOGY Vol. 23 (pp. 10-11). Barcelona, SPAIN: OXFORD UNIV PRESS. |
| 2012 | Ransom, D., Wilson, K., Bishnoi, S. K., Simes, J., Yip, D., Karapetis, C. S., . . . Price, T. J. (2012). Results of Australasian Gastrointestinal Trials Group (AGITG) Arctic study: An international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines (FP).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. |
| 2011 | Bishnoi, S., Price, T., Beeke, C., Karapetis, C., Townsend, A., Maddern, G., & Padbury, R. (2011). Liver Only Metastatic Disease in Patients With Metastatic Colorectal Cancer (mCRC), Impact of Surgery and Chemotherapy. In EUROPEAN JOURNAL OF CANCER Vol. 47 (pp. S403). Stockholm, SWEDEN: ELSEVIER SCI LTD. DOI |
| 2011 | Price, T., Peeters, M., Strickland, A., Ciuleanu, T. E., Scheithauer, W., O'Reilly, S., . . . Kartik, K. (2011). Efficacy of Panitumumab Plus FOLFIRI Versus FOLFIRI Alone in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) Treated With Prior Oxaliplatin or Bevacizumab Regimens: Results From 20050181. In EUROPEAN JOURNAL OF CANCER Vol. 47 (pp. S431-S432). Stockholm, SWEDEN: ELSEVIER SCI LTD. DOI WoS1 |
| 2011 | Peeters, M., Price, T., Strickland, A., Ciuleanu, T. -E., Scheithauer, W., O'Reilly, S., . . . Krishnan, K. (2011). EVALUATION OF PANITUMUMAB (PMAB) PLUS FOLFIRI VERSUS FOLFIRI ALONE AS SECOND-LINE THERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING PRIOR BEVACIZUMAB (BEV) IN STUDY 20050181. In ANNALS OF ONCOLOGY Vol. 22 (pp. v103-v104). Barcelona, SPAIN: OXFORD UNIV PRESS. |
| 2011 | Shapiro, J. D., Siu, L. L., Zalcberg, J. R., Moore, M. J., Ringash, J., Mittmann, N., . . . Jonker, D. J. (2011). A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 29 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. DOI WoS4 |
| 2011 | Price, T. J., Zannino, D., Wilson, K., Simes, J., Van Hazel, G. A., Robinson, B. A., . . . Tebbutt, N. C. (2011). Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 29 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. DOI |
| 2011 | Peeters, M., Price, T. J., Strickland, A. H., Ciuleanu, T. E., Scheithauer, W., O'Reilly, S., . . . Krishnan, K. (2011). Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181. In JOURNAL OF CLINICAL ONCOLOGY Vol. 29 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. DOI |
| 2011 | Weickhardt, A. J., Williams, D., Lee, C., Simes, J., Murone, C., Wilson, K., . . . Tebbutt, N. C. (2011). Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 29 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. WoS27 |
| 2010 | Andre, T., Peeters, M., Price, T., Hotko, Y., Cervantes, A., Ducreux, M., . . . Gansert, J. (2010). PANITUMUMAB WITH FOLFIRI VS FOLFIRI ALONE: A RANDOMISED PHASE 3 STUDY FOR THE SECOND LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC). In ANNALS OF ONCOLOGY Vol. 21 (pp. I13). Nice, FRANCE: OXFORD UNIV PRESS. |
| 2010 | Peeters, M., Price, T., Hotko, Y., Cervantes, A., Ducreux, M., Andre, T., . . . Gansert, J. (2010). RANDOMIZED PHASE 3 STUDY OF PANITUMUMAB (PMAB) WITH FOLFIRI COMPARED TO FOLFIRI ALONE AS SECOND-LINE TREATMENT (TX) FOR METASTATIC COLORECTAL CANCER (MCRC): SECONDARY ENDPOINT RESULTS. In ANNALS OF ONCOLOGY Vol. 21 (pp. 15). Barcelona, SPAIN: OXFORD UNIV PRESS. WoS2 |
| 2010 | Lordick, F., Peeters, M., Price, T., Hotko, Y., Cervantes, A., Ducreux, M., . . . Gansert, J. (2010). Panitumumab with FOLFIRI versus FOLFIRI alone: results from a randomised phase III study of second-line treatment of patients with metastatic colorectal cancer (mCRC). In ONKOLOGIE Vol. 33 (pp. 3). KARGER. |
| 2010 | Price, T. J., Hardingham, J., Lee, C., Weickhardt, A., Townsend, A., Wrin, J. W., . . . Tebbutt, N. (2010). IMPACT OF KRAS AND BRAF GENE MUTATION STATUS ON OUTCOMES FROM THE PHASE III AGITG MAX TRIAL OF CAPECITABINE (C) ALONE OR IN COMBINATION WITH BEVACIZUMAB (B) ± MITOMYCIN C (M) IN ADVANCED COLORECTAL CANCER (CRC). In ANNALS OF ONCOLOGY Vol. 21 (pp. 198). Milan, ITALY: OXFORD UNIV PRESS. |
| 2010 | Jain, K., Strickland, A. H., Slavotinek, J., Eaton, M., McLeay, W., Price, T. J., . . . Karapetis, C. S. (2010). A RANDOMISED TRIAL COMPARING PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS (PICC) VS SUBCUTANEOUSLY IMPLANTED PORT-CHAMBER CATHETERS (PORT) FOR DELIVERY OF CHEMOTHERAPY TO PATIENTS WITH NON-HAEMATOLOGICAL MALIGNANCIES. In ANNALS OF ONCOLOGY Vol. 21 (pp. 383-384). Milan, ITALY: OXFORD UNIV PRESS. |
| 2010 | Townsend, A., Price, T. J., Beeke, C., Karapetis, C., Luke, C., Roder, D., . . . Padbury, R. (2010). PRELIMINARY RESULTS FROM THE SOUTH AUSTRALIAN (SA) CLINICAL REGISTRY FOR ADVANCED COLORECTAL CANCER (CRC) ASSESSING THE IMPACT OF AGE AND CHOICE OF CHEMOTHERAPY ON OUTCOME. In ANNALS OF ONCOLOGY Vol. 21 (pp. 203-204). Milan, ITALY: OXFORD UNIV PRESS. WoS1 |
| 2010 | Haller, D., Cassidy, J., Tabernero, J., Maroun, J. A., De Braud, F., Price, T. J., . . . Schmoll, H. (2010). RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): IMPACT OF AGE ON DISEASE-FREE SURVIVAL (DFS) OR OVERALL SURVIVAL (OS). In ANNALS OF ONCOLOGY Vol. 21 (pp. 207). Milan, ITALY: OXFORD UNIV PRESS. WoS2 |
| 2010 | Haller, D., Cassidy, J., Tabernero, J., Maroun, J., De Braud, F., Price, T., . . . Schmoll, H. (2010). EFFICACY FINDINGS FROM A RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL. In ANNALS OF ONCOLOGY Vol. 21 (pp. 12). Barcelona, SPAIN: OXFORD UNIV PRESS. |
| 2009 | Spencer, A., Millward, M., Mainwaring, P., Harrison, S., Catley, L., Townsend, A., . . . Price, T. (2009). Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052. In BLOOD Vol. 114 (pp. 1053-1054). New Orleans, LA: AMER SOC HEMATOLOGY. WoS1 |
| 2009 | Hailer, D., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., . . . Schmoll, H. (2009). First efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). In EJC SUPPLEMENTS Vol. 7 (pp. 4). Berlin, GERMANY: PERGAMON-ELSEVIER SCIENCE LTD. |
| 2009 | Tebbutt, N. C., Gebski, V., Wilson, K., Cummins, M., Chua, Y., Robinson, B., . . . Price, T. (2009). International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 2 pages). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. WoS2 |
| 2009 | Tebbutt, N., Gebski, V., Wilson, K., Cummins, M., Robinson, B., Broad, A., . . . Price, T. (2009). International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial. In EJC SUPPLEMENTS Vol. 7 (pp. 321). Berlin, GERMANY: PERGAMON-ELSEVIER SCIENCE LTD. DOI WoS2 |
| 2009 | Sukumaran, S., Pavlakis, N., Pittman, K. B., Patterson, K., & Price, T. J. (2009). Capecitabine and irinotecan (XELIRI) in first-line treatment of metastatic colorectal cancer (mCRC): A systematic review of controlled clinical trials. In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. WoS1 |
| 2009 | Peeters, M., Price, T., Hotko, Y., Cervantes, A., Ducreux, M., Andre, T., . . . Gansert, J. (2009). Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). In EJC SUPPLEMENTS Vol. 7 (pp. 10). Berlin, GERMANY: PERGAMON-ELSEVIER SCIENCE LTD. DOI WoS9 |
| 2009 | Townsend, A. R., Millward, M., Price, T., Mainwaring, P., Spencer, A., Longenecker, A., . . . Padrik, P. (2009). Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 2 pages). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. WoS11 |
| 2009 | Price, T. J., Peeters, M., Douillard, J., Mitchell, E., Cohn, A., Strickland, A. H., . . . Siena, S. (2009). Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 2 pages). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. WoS14 |
| 2009 | Millward, M., Spear, M. A., Townsend, A., Sweeney, C., Sukumaran, S., Longenecker, A., . . . Price, T. (2009). Clinical trial combining proteasome (NPI-0052) and HDAC (vorinostat) inhibition in melanoma, pancreatic, and lung cancer. In MOLECULAR CANCER THERAPEUTICS Vol. 8 (pp. 3 pages). AMER ASSOC CANCER RESEARCH. DOI |
| 2009 | Price, T., Millward, M., Mainwaring, P., Harrison, S., Galley, L., Townsend, A., . . . Spencer, A. (2009). A two-arm phase 1 clinical trial with NPI-0052, a novel proteasome inhibitor. In MOLECULAR CANCER THERAPEUTICS Vol. 8 (pp. 3 pages). AMER ASSOC CANCER RESEARCH. DOI WoS1 |
| 2008 | Peeters, M., Wilson, G., Ducreux, M., Cervantes, A., Andre, T., Hotko, Y., . . . Price, T. J. (2008). Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results. In JOURNAL OF CLINICAL ONCOLOGY Vol. 26 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. |
| 2008 | Kichenadasse, G., Townsend, A., & Price, T. (2008). Rectal cancers in the elderly - Lessons learned. In Cancer Forum Vol. 32 (pp. 20-22). AUSTRALIAN CANCER SOC INC. Scopus1 |
| 2008 | Kotasek, D., Tebbutt, N., Welch, S., Hei, Y., McCoy, S., Sun, Y., . . . Price, T. (2008). SAFETY AND PHARMACOKINETICS (PK) OF MOTESANIB DIPHOSPHATE IN COMBINATION WITH GEMCITABINE AND ERLOTINIB FOR THE TREATMENT OF SOLID TUMORS. In ANNALS OF ONCOLOGY Vol. 19 (pp. 159-160). Stockholm, SWEDEN: OXFORD UNIV PRESS. WoS1 |
| 2008 | Price, T. J., Gebski, V., van Hazel, G., Robinson, B., Broad, A., Ganju, V., . . . Tebbutt, N. (2008). SAFETY ANALYSIS OF AN INTERNATIONAL MULTI-CENTRE RANDOMISED PHASE II/III STUDY OF CAPECITABINE (CAP), BEVACIZUMAB (BEV) AND MITOMYCIN C (MMC) IN METASTATIC COLORECTAL CANCER (MCRC): AGITG MAX TRIAL. In ANNALS OF ONCOLOGY Vol. 19 (pp. 127). Stockholm, SWEDEN: OXFORD UNIV PRESS. |
| 2008 | Townsend, A., Price, T. J., Yeend, S., Pittman, K., Patterson, K., & Luke, C. (2008). METASTATIC CARCINOID TUMOR (MCT): SURVIVAL IMPROVED WITH OCTREOTIDE LAR (OLAR). In ANNALS OF ONCOLOGY Vol. 19 (pp. 248). Stockholm, SWEDEN: OXFORD UNIV PRESS. |
| 2008 | Padrik, P., Price, T. J., Spear, M. A., Townsend, A., Longenecker, A., Palladino, M. A., . . . Millward, M. (2008). PHASE 1 STUDY OF THE NOVEL PROTEASOME INHIBITOR NPI-0052 IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING LEUKEMIAS. In ANNALS OF ONCOLOGY Vol. 19 (pp. 162). Stockholm, SWEDEN: OXFORD UNIV PRESS. WoS2 |
| 2008 | Townsend, A., Padrik, P., Mainwaring, P., Price, T., Catley, L., Longenecker, A., . . . Millward, M. (2008). Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D. In EJC SUPPLEMENTS Vol. 6 (pp. 74). Geneva, SWITZERLAND: PERGAMON-ELSEVIER SCIENCE LTD. DOI WoS1 |
| 2007 | Michael, M., Price, T., Leong, T., Ganju, V., Strickland, A., Jefford, M., . . . Zalcberg, J. (2007). Phase I trial of capecitabine and gemcitabine with concurrent radical radiotherapy in locally advanced pancreatic cancer: final results. In EJC SUPPLEMENTS Vol. 5 (pp. 272). Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD. DOI WoS1 |
| 2007 | Price, T. J., Morelli, L., Howarth, G. S., Webster, J., Zacharakis, B., Brooker, C., . . . Butler, R. N. (2007). Residual damage to the small intestine induced by chemotherapy can be detected and monitored using the non-invasive <SUP>13</SUP>C Sucrose Breath Test (SBT). In EJC SUPPLEMENTS Vol. 5 (pp. 152). Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD. DOI |
| 2006 | Schmoll, H., Tabernero, J., Nowacki, M., Maroun, J., Price, T., Lim, R., . . . Haller, D. (2006). Capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer: Final safety findings from a randomized phase III trial. In ANNALS OF ONCOLOGY Vol. 17 (pp. 25-26). Barcelona, SPAIN: OXFORD UNIV PRESS. |
| 2006 | Schmoll, H. J., Tabernero, J., Nowacki, M., Maroun, J., Price, T., Lim, R., . . . Haller, D. (2006). Final safety findings from a randomized phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 24 (pp. 163S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY. WoS4 |
| 2006 | Michael, M., Leong, T., Price, T. J., Ganju, V., Strickland, A., Jefford, M., . . . Zalcberg, J. R. (2006). Phase I trial of capecitabine (CAP) and gemcitabine (GEM) with concurrent radical radiotherapy in locally advanced pancreatic cancer (PAC): Initial results. In ANNALS OF ONCOLOGY Vol. 17 (pp. 311). Istanbul, TURKEY: OXFORD UNIV PRESS. DOI |
| 2006 | Price, T. J., Roder, D., Pittman, K., Patterson, K., Rieger, N., Hewett, P., . . . Luke, C. (2006). Survival trends for advanced colorectal cancer (CRC): Are improvements only for patients in clinical trials?. In JOURNAL OF CLINICAL ONCOLOGY Vol. 24 (pp. 331S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY. |
| 2006 | Leong, T., Michael, M., Price, T., Ganju, V., Strickland, A., Jefford, M., . . . Zalcberg, J. (2006). Phase I trial of capecitabine and gemcitabine with radiotherapy in locally advanced pancreatic cancer. In ANNALS OF ONCOLOGY Vol. 17 (pp. 34). Barcelona, SPAIN: OXFORD UNIV PRESS. |
| 2005 | Price, T. J., Zakaria, J., Rodda, D., Hewett, P., Rieger, N., Stephens, J., . . . Borg, M. (2005). Squamous cell carcinoma of the anal canal at the Queen Elizabeth Hospital: A local experience.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 559S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. |
| 2005 | Thomson, D. B., Gonzalez, R., Millward, M., Price, T., Haydon, A., Robinson, W., . . . Creese, B. (2005). A phase II trial of PI-88, a novel antiangiogenic and antimetastatic heparanase inhibitor, in patients with advanced melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 724S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. |
| 2005 | Schmoll, H. J., Tabernero, J., Nowacki, M., Maroun, J., Figer, A., Price, T., . . . Braud, F. (2005). Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 251S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. WoS7 |
| 2005 | Pittman, K. B., Olver, I. N., Karapetis, C. S., Kotasek, D., Price, T. J., Patterson, W. K., . . . Greer, D. (2005). Mulicenter phase II study of gemcitabine and carboplatin combination therapy for patients with metastatic carcinoma of unknown primary site: final results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 764S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. WoS1 |
| 2004 | Price, T. J., Pittman, K., Patterson, K., Colbeck, M., Sim, S., Roder, D., . . . Luke, C. (2004). Survival and treatment trends for advanced colorectal cancer (CRC) treated in a University Hospital, 1992-2001.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 22 (pp. 295S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY. |
| 2003 | Rao, S., Cunningham, D., Ross, P. J., Price, T., Watkins, D., Norman, A. R., . . . Hill, M. E. (2003). A phase II trial of capecitabine and mitomycin C (MMC) in 1<SUP>st</SUP> line treatment of metastatic colorectal cancer (MCRC).. In BRITISH JOURNAL OF CANCER Vol. 88 (pp. S58). BOURNEMOUTH, ENGLAND: NATURE PUBLISHING GROUP. |
| 2003 | Rao, S., Cunningham, D., Ross, P. J., Price, T., Ward, C., Norman, A. R., & Hill, M. E. (2003). Capecitabineand mitomycin C (MMC) is an active regimen for patients with metastatic colorectal carcinoma (MCRC) resistant to 5FU and irinotecan. In BRITISH JOURNAL OF CANCER Vol. 88 (pp. S56). BOURNEMOUTH, ENGLAND: NATURE PUBLISHING GROUP. |
| 1999 | Ross, P., Cunningham, D., Scarffe, H., Nicolson, M., Seymour, M., Harper, P., . . . Norman, A. (1999). Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer. In EUROPEAN JOURNAL OF CANCER Vol. 35 (pp. S137). PERGAMON-ELSEVIER SCIENCE LTD. DOI WoS3 |
| Year | Citation |
|---|---|
| 2022 | Krishnan, T., Piantadosi, C., Karapetis, C., Townsend, A., Roy, A., Geerinckx, B., . . . Price, T. (2022). First-line anti-EGFR or anti-VEGF therapy in metastatic colorectal cancer (mCRC) by tumour sidedness: Results from the South Australian mCRC registry. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. |
| 2021 | Adams, J., Vanlint, A., & Price, T. (2021). COVID-19 prompts rapid and safe transition of chemotherapy into homes. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. DOI |
| 2020 | Nakhjavani, M., Smith, E., Price, T., Townsend, A., & Hardingham, J. (2020). PS11-38. Ginsenoside Rg3 enantiomers in a defined ratio as a novel treatment for metastatic triple-negative breast cancer. Poster session presented at the meeting of San Antonio Breast Cancer Symposium. San Antonio, TX U.S.A.. |
| 2019 | Smith, E., Tomita, Y., Palethorpe, H., Howell, S., Nakhjavani, M., Townsend, A., . . . Hardingham, J. (2019). Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation and improved overall survival. Poster session presented at the meeting of 31st Lorne Cancer Conference. Lorne, VIC, Australia. |
| 2019 | Tie, J., Cohen, J., Wang, Y., Li, L., Lee, M., Wong, R., . . . Gibbs, P. (2019). A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2019 | Prasanna, T., Wong, R., Price, T. J., Shapiro, J. D., Tie, J., Wong, H. -L., . . . Yip, D. (2019). Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2019 | Taieb, J., Price, T. J., Ciardiello, F., Peeters, M., Wyrwicz, L., Bachet, J. -B., . . . Falcone, A. (2019). Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2018 | Taieb, J., Geissler, M., Rivera, F., Karthaus, M., Wilson, R., Loupakis, F., . . . Peeters, M. (2018). Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies. Poster session presented at the meeting of Annals of oncology : official journal of the European Society for Medical Oncology. Barcelona, SPAIN: OXFORD UNIV PRESS. DOI Scopus1 |
| 2018 | Leung, J. T., Roy, A., Price, T., & Singhal, N. (2018). Phase 1 trial of nab-paclitaxel administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma. Poster session presented at the meeting of ASCO 2014. United States: LIPPINCOTT WILLIAMS & WILKINS. DOI Scopus2 WoS2 Europe PMC2 |
| 2018 | Palethorpe, H. M., Tomita, Y., Smith, E., Townsend, A. R., Price, T. J., Yool, A. J., & Hardingham, J. E. (2018). Bacopaside II reduces endothelial cell migration and angiogenesis in vitro. Poster session presented at the meeting of 30th Lorne Cancer Conference. Lorne. |
| 2018 | Smith, E., Palethorpe, H. M., Tomita, Y., Townsend, A. R., Price, T. J., Yool, A. J., & Hardingham, J. E. (2018). Anti-tumour effects of Bacopaside II on colorectal cancer cells in vitro. Poster session presented at the meeting of 30th Lorne Cancer Conference. Lorne, VIC. |
| 2018 | Bernhardt, S., Townsend, A., Price, T., & Ingman, W. (2018). Hormonal modulation of breast cancer gene expression and implications for diagnosis and treatment of premenopausal women. Poster session presented at the meeting of CLINICAL ENDOCRINOLOGY. Perth, AUSTRALIA: WILEY. |
| 2018 | Abbas, N., Barnes, M., Price, T., Karapetis, C., Bright, T., Bull, J., . . . Roy, A. (2018). Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit. Poster session presented at the meeting of Annals of oncology : official journal of the European Society for Medical Oncology. Barcelona, SPAIN: OXFORD UNIV PRESS. DOI |
| 2017 | Mooi, J., Wirapati, P., Asher, R., Lee, C., Savas, P., Price, T. J., . . . Tebbutt, N. (2017). Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: OXFORD UNIV PRESS. |
| 2017 | Michael, M., Liauw, W., McLachlan, S. -A., Link, E., Matera, A., Thompson, M., . . . Burge, M. E. (2017). Hepatic functional imaging and genomics to predict irinotecan pharmacokinetics and pharmacodynamics: The PREDICT IR study. Poster session presented at the meeting of Abstracts of the 42nd European Society for Medical Oncology Congress (ESMO 2017), as published in Annals of Oncology. Madrid, SPAIN: Elsevier. DOI |
| 2016 | Roy, A., Price, T., Townsend, A., Piantadosi, C., Padbury, R., Moore, J., . . . Karapetis, C. (2016). TREATMENT AND OUTCOMES OF METASTATIC COLORECTAL CANCER PATIENTS IN PUBLIC AND PRIVATE HOSPITALS: RESULTS FROM THE SOUTH AUSTRALIAN METASTATIC COLORECTAL CANCER REGISTRY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. |
| 2016 | Wong, S., Lidums, I., Parry, S., Win, A. K., Vatandoust, S., Patel, D., . . . Young, J. P. (2016). Characteristics of Advanced Neoplasia of the Large Bowel in Young Adults: Results From a Hospital Colonoscopy Service Database. Poster session presented at the meeting of GASTROINTESTINAL ENDOSCOPY. MOSBY-ELSEVIER. DOI |
| 2016 | Townsend, A., Tebbutt, N., Karapetis, C., Cooper, P., Singhal, N., Yeend, S., . . . Price, T. J. (2016). A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT). Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS. DOI Scopus1 WoS1 |
| 2016 | Price, T., Karapetis, C., Piantadosi, C., Rico, G. T., Padbury, R., Maddern, G., . . . Townsend, A. (2016). Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Netherlands: OXFORD UNIV PRESS. DOI |
| 2016 | Ayoola, A., Vantandoust, S., Roy, A., Price, T. J., Kitchener, M., Roder, D., . . . Karapetis, C. (2016). Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): safety, efficacy and survival outcomes from the South Australian registry. Poster session presented at the meeting of Annals of Oncology. Netherlands: Elsevier. DOI |
| 2016 | Price, T. J., Douillard, J. Y., Guan, X., Bohac, C., & Peeters, M. (2016). Associations between dermatologic toxicity severity, patient characteristics, and efficacy among patients treated with panitumumab (Pmab) and chemotherapy. Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS. DOI |
| 2016 | Diakos, C. I., Tu, D., Gebski, V., Yip, S., Wilson, K., Karapetis, C. S., . . . Clarke, S. (2016). Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies. Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS. DOI Scopus2 WoS3 |
| 2016 | Schmoll, H. J., Stein, A., Hofheinz, R. D., Price, T. J., Nordlinger, B., Daisne, J. F., . . . Haustermans, K. (2016). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: final analyses. Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS. DOI Scopus10 WoS3 |
| 2016 | Diakos, C. I., Wilson, K., Asher, R., Gebski, V., Yip, S., van Hazel, G., . . . Clarke, S. (2016). Is baseline neutrophil to lymphocyte ratio (NLR) an independent prognostic biomarker for progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC)? Analysis of the AGITG MAX study. Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS. DOI Scopus5 WoS4 |
| 2015 | Patel, D., Broadbridge, V., Hardingham, J., Colbeck, M., Pittman, K., Townsend, A., . . . Price, T. (2015). OUTCOME FOR EARLY STAGE RECTAL CANCER NOT IMPROVED OVER TIME FOR THOSE AGED ≥75 YEARS: ANALYSIS OF SINGLE CENTRE CANCER REGISTRY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. |
| 2015 | Tomita, Y., Karapetis, C. S., Ullah, S., Townsend, A. R., Padbury, R., & Price, T. J. (2015). Survival improvement associated with access to biological agents: Updated results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2015 | Vatandoust, S., Roy, A. C., Price, T. J., Ullah, S., Beeke, C., Townsend, A. R., . . . Karapetis, C. S. (2015). Survival impact of primary tumor resection in patients (pts) with unresectable metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2 |
| 2015 | Price, T. J., Tomita, Y., Beeke, C., Padbury, R., Townsend, A. R., Maddern, G., . . . Karapetis, C. S. (2015). Survival for patients with resectable lung metastatic colorectal cancer (mCRC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS5 |
| 2015 | Chan, D. L., Leyden, J., Michael, M., Price, T. J., Clarke, S., Pavlakis, N., & Khasraw, M. (2015). SYMPTOM BURDEN OF AUSTRALIA AND NEW ZEALAND (ANZ) PATIENTS WITH NEUROENDOCRINE TUMOURS (NET). Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL. |
| 2015 | Chan, D. L., Leyden, J., Price, T. J., Michael, M., Clarke, S., Diakos, C., . . . Pavlakis, N. (2015). EXPERIENCE OF AUSTRALIA AND NEW ZEALAND (ANZ) PATIENTS WITH NEUROENDOCRINE TUMOURS (NET) TREATED AT A NET SPECIALIST CENTRE: RESULTS OF A NATIONAL SURVEY AND THE ROYAL NORTH SHORE EXPERIENCE. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL. |
| 2015 | Leyden, J., Pavlakis, N., Chan, D., Michael, M., Clarke, S., Khasraw, M., & Price, T. (2015). NEUROENDOCRINE TUMOR (NET) OCEANIA PATIENT EXPERIENCE: RESULTS FROM THE FIRST GLOBAL NET PATIENT SURVEY - A COLLABORATION BETWEEN THE INTERNATIONAL NEUROENDOCRINE CANCER ALLIANCE (INCA) AND NOVARTIS. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL. |
| 2014 | Charakidis, M., Hocking, C., Pittman, K., Townsend, A., Hsieh, A. H. C., & Price, T. (2014). IMMUNOHISTOCHEMISTRY DIRECTED THERAPY IN CARCINOMA OF UNKNOWN PRIMARY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. |
| 2014 | Price, T. J., Beeke, C., Padbury, R., Maddern, G., Roder, D., Moore, J., . . . Karapetis, C. S. (2014). Right (R) or left (L) primary site of colorectal cancer and outcomes for metastatic colorectal cancer (mCRC): Results from the south Australian registry of mCRC.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2014 | Price, T. J., Townsend, A. R., Bruhn, M., Lee, C., Wrin, J., Shivasami, A., . . . Hardingham, J. (2014). Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer (mCRC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY. DOI |
| 2014 | Baylock, B., Dhillon, H. M., Goddard, E. M., Turner, J., Rice, H., Kabourakis, M., . . . Vardy, J. L. (2014). THE COLON HEALTH AND LIFE-LONG EXERCISE CHANGE (CHALLENGE) TRIAL: PARTICIPANT ADHERENCE TO FITNESS ASSESSMENTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. WoS1 |
| 2014 | Vatandoust, S., Karapetis, C. S., Padman, S. J., Beeke, C., Padbury, R., Kitchener, M., . . . Price, T. J. (2014). THE MANAGEMENT OF COLORECTAL CANCER (CRC) LIVER METASTASES WITH YTTRIUM-90 MICROSPHERES (Y90), THE SOUTH AUSTRALIAN (SA) EXPERIENCE. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. |
| 2014 | Chan, D., Pavlakis, N., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., & Segelov, E. (2014). IMPACT OF CHEMOTHERAPY PARTNER ON EFFICACY OF TARGETED AGENTS IN METASTATIC COLORECTAL CANCER (MCRC): SYSTEMATIC REVIEW AND META-ANALYSIS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. WoS1 |
| 2013 | Chan, D., Segelov, E., Shapiro, J., Price, T. J., Karapetis, C. S., Tebbutt, N., & Pavlakis, N. (2013). META-ANALYSIS OF PROGRESSION-FREE SURVIVAL IMPACT OF BIOLOGICAL THERAPY IN RELAPSED METASTATIC COLORECTAL CANCER. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. |
| 2013 | Peeters, M., Douillard, J. Y., Siena, S., Price, T., Tabernero, J., Sidhu, R., . . . Rong, A. (2013). Impact of post-protocol anti-epidermal growth factor receptor therapy on survival in wild-type KRAS/NRAS metastatic colorectal cancer: Data from the PRIME study. Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. WoS1 |
| 2013 | Price, T., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., . . . Sidhu, R. (2013). ASPECCT: A randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. WoS2 |
| 2013 | Peeters, M., Douillard, J. Y., Siena, S., Price, T., Tabernero, J., Sidhu, R., . . . Davison, C. (2013). Impact of post-progression anti-vascular endothelial growth factor-containing therapy on survival in patients with metastatic colorectal cancer: Data from the PRIME study. Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. WoS2 |
| 2013 | Price, T., Hocking, C., Broadbridge, V., Wrin, J., Townsend, A. R., Tebbutt, N., . . . Hardingham, J. (2013). Can we accurately report PTEN status in advanced colorectal cancer?. Poster session presented at the meeting of European Cancer Congress 2013 Abstract Book, as published in European Journal of Cancer. Amsterdam, Netherlands: Elsevier. DOI |
| 2013 | Price, T. J., Pirc, L., Cooper, P., Tebbutt, N., Karapetis, C., Singhai, N., & Townsend, A. R. (2013). A phase 1B study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT). Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. |
| 2013 | Vatandoust, S., Joshi, R., Pittman, K., Esterman, A., Broadbridge, V., Adams, J., . . . Price, T. (2013). A descriptive study of persistent oxaliplatin induced peripheral neuropathy in patients with colorectal cancer. Poster session presented at the meeting of Abstracts of the Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Blood, Biomarkers and Beyond, 31 July - 2 August 2013, as published in Asia-Pacific Journal of Clinical Oncology. Melbourne, Victoria: Wiley-Blackwell. DOI |
| 2013 | Townsend, A. R., Pirc, L., Cooper, P., Tebbutt, N. C., Karapetis, C. S., Singhal, N., & Price, T. J. (2013). A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. WoS2 |
| 2012 | Schmoll, H. -J., Tabernero, J., Maroun, J., De Braud, F., Price, T., Van Cutsem, E., . . . Haller, D. (2012). The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. |
| 2012 | Siu, L., Shapiro, J., Jonker, D., Karapetis, C., Zalcberg, J., Simes, J., . . . O'Callaghan, C. (2012). Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. |
| 2012 | Vatandoust, S., Joshi, R., Broadbridge, V., Pittman, K. B., Adams, J., Singhal, N., . . . Price, T. J. (2012). Persistent oxaliplatin (OX) induced peripheral neuropathy in patients (pts) with colorectal cancer: A descriptive study.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. |
| 2012 | Price, T. J., Hardingham, J., Lee, C., Wrin, J., Townsend, A. R., Wilson, K., . . . Tebbutt, N. C. (2012). Analysis of PTEN in patients with advanced colorectal cancer (CRC) receiving capecitabine alone or in combination with bevacizumab with or without mitomycin C in the phase III AGITG MAX trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. |
| 2010 | Pittman, K. B., Colbeck, M., Price, T. J., Sukumaran, S., Hooper, B., Tuck, M., . . . Hardingham, J. (2010). PATTERNS OF CARE AND INFLUENCE ON SURVIVAL IN SMALL CELL LUNG CANCER: A SINGLE AUSTRALIAN ONCOLOGY UNIT EXPERIENCE. Poster session presented at the meeting of JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. |
| Year | Citation |
|---|---|
| 2025 | Kianpour Rad, S., Li, R., Yeo, K., Wu, F., Tomita, Y., Price, T., . . . Smith, E. (2025). Bacterial Infection and Their Cell Wall Ligands Differentially Modulate Doxorubicin Sensitivity in Triple‐Negative Breast Cancer Cells. DOI |
| 2024 | Li, R., Liu, S., Yeo, K., Edwards, S., Li, M. Y., Santos, R., . . . Smith, E. (2024). Circulating SFRP5 levels are elevated in colorectal cancer and correlate with overall survival in stage II-III disease. DOI |
| Date | Project Title | Investigators | Funding Body | Amount |
|---|---|---|---|---|
| 2015-17 | SCOT Study – Short Course Oncology Therapy – a study of adjuvant chemotherapy in colorectal cancer | A Haydon, J Zalcberg, E Walpole, D Yip, TJ Price et al. | Cancer Australia | 150,000 |
| 2014-2017 | Individualised Risk Assessment and Therapeutic Intervention for Colorectal Cancer in the South Australian Population | G Maddern, J Young, TJ Price et al. | SAHMRI BEAT Cancer Hospital Research grant | 1,500,000 |
| Innovative Cancer Imaging and Therapeutics Facility | C Mulligan, T Hughes, A Zannettino, S Grothos, D White, D Keefe, T Monro, D Roder, W Tilley, TJ Price, P MacKenzie | Australian Cancer Research Founda | 1,800,000 | |
| 2013 | PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer | TJ Price | Cancer Australia + Cancer Council NSW | 123,331 + 19,624 |
| 2012 | Impact of the activated EGFR-AKT-mTOR signalling pathway on prognosis and tumour resistance to anti-angiogenic targeted therapy for metastatic colorectal cancer | A Townsend, JE Hardingham, TJ Price, N Tebbutt | Cancer Council of South Australia | 92,678 |
| 2009 - 2011 | SCOT Study – Short Course Oncology Therapy – a study of adjuvant chemotherapy in colorectal cancer | A Haydon, J Zalcberg, E Walpole, D Yip, TJ Price, M Jefford, K Howard | Cancer Australia | 599,000 |
| 2009 | A new prognostic multi-marker assay for early stage bowel cancer | J Hardingham, P Hewett, T Price, T Chataway | Cancer Council SA | 89,750 |
| 2009 - 2011 | PETACC 6 trial, neoadjuvant chemotherapy for T3/T4 rectal carcinoma | TJ Price, J Harvey, N Tebbutt, J Zalcberg, J Simes, G Hururby | Cancer Australia | 477,800 |
I am involved in the cancer curriculum initially overseeing the curriculum for 4th year Medical Students and involvement in 5th year Medical Student lecturing. As the cancer curriculum evolved over time my involvement with Medical Student Teaching has primarily been clinical based on the Oncology placements. This includes direct patient teaching together with tutorial style teaching at the time of clinics and during ward rounds.
I am actively involved in the Physician Training Program having been involved in the pre-written exam tutorial program and I have been part of the National Examining Panel (NEP) for the College of Physicians for over ten years and continue to be part of the panel. This of course involves ongoing involvement in the long case program within the Queen Elizabeth Hospital, and previously also at the Lyell McEwin Health Service. I am also involved in the Medical Oncology Advanced Training Tutorial Program lecturing on gastrointestinal cancer and in particular colorectal cancer.
As part of my University of Adelaide teaching duties I have established the TQEH campus Nurse Practitioner Candidate (NPC) clinical course, facilitating clinical placements as well as direct supervision of the NPC. This training program consists of direct clinical skill training, supervision of patient clinic practice as well as tutorial program. I have also had involvement in teaching of the Rural NPC via as part of my clinical attachment both with direct patient skill training and additional instruction in telemedicine skill training. In addition to NPC teaching, I also have Flinders University Medical student placements in Mount Gambier.
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2025 | Principal Supervisor | KRAS mutations (G12 and G13) predicting resistance to trifluridine/tipiracil (Lonsurf) in patients with metastatic colorectal cancer | Master of Clinical Science | Master | Full Time | Dr Ayesha Salim |
| 2025 | Principal Supervisor | KRAS mutations (G12 and G13) predicting resistance to trifluridine/tipiracil (Lonsurf) in patients with metastatic colorectal cancer | - | Master | Full Time | Dr Ayesha Salim |
| 2022 | Co-Supervisor | Over-expression of SFRP5 in hepatocytes: a novel treatment strategy for colorectal cancer liver metastases | Doctor of Philosophy | Doctorate | Full Time | Mr Runhao Li |
| 2022 | Co-Supervisor | Over-expression of SFRP5 in hepatocytes: a novel treatment strategy for colorectal cancer liver metastases | Doctor of Philosophy | Doctorate | Full Time | Mr Runhao Li |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2018 - 2022 | Principal Supervisor | Towards an Understanding of the Growing Incidence of Colorectal Cancer and Appendiceal Neoplasms in Young Adults | Doctor of Philosophy | Doctorate | Full Time | Mr Reger Romi Mikaeel |
| 2016 - 2020 | Co-Supervisor | The effect of menstrual cycling on genomic predictive biomarkers in premenopausal breast cancer | Doctor of Philosophy | Doctorate | Full Time | Miss Sarah Margaret Bernhardt |
| 2015 - 2021 | Co-Supervisor | Evaluation of Anti-Cancer Effect of Synthetic and Plant-based Inhibitors of Aquaporin 1 in Colon Cancer | Doctor of Philosophy | Doctorate | Part Time | APrf Yoko Tomita |
| 2011 - 2015 | Co-Supervisor | Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines | Doctor of Philosophy | Doctorate | Full Time | Miss Shalini Sree Kumar |
| Date | Role | Board name | Institution name | Country |
|---|---|---|---|---|
| 2015 - ongoing | Member | Executive committee | Clinical Oncology Society of Australia (COSA) | Australia |
| 2015 - ongoing | Chair | Colorectal Guidelines Management Committee | NHMRC/Cancer Council Austra | Australia |
| 2014 - ongoing | Board Member | Gastrointestinal Cancer Institute New Zealand | - | New Zealand |
| 2014 - ongoing | Chair | Australasian Gastrointestinal Trials Group | - | Australia |
| Date | Role | Membership | Country |
|---|---|---|---|
| 2002 - ongoing | Member | European Society of Medical Oncology | Sweden |
| 2000 - ongoing | Member | American Society of Clinical Oncology | United States |
Connect With Me
External Profiles
